



43rd NATIONAL CONGRESS

OF THE ITALIAN SOCIETY OF PHARMACOLOGY

CREATING VALUE THROUGH
PHARMACOLOGICAL RESEARCH

TURIN CENTRO CONGRESSI LINGOTTO

25-28 NOVEMBER 2026

SOCIETÀ ITALIANA
DI FARMACOLOGIA

3PSOLUTION

WITH THE PATRONAGE OF

AIFA AGENZIA ITALIANA DEL FARMACO

CONFERENZA DELLE REGIONI E DELLE PROVINCE AUTONOME

UNIVERSITÀ DI TORINO

FNOMCeO Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri

Federazione Ordini Farmacisti Italiani FOFI

FIMMG Federazione Italiana Medici di Famiglia

FISM Federazione delle Società Medico-Scientifiche Italiane

SIMG SOCIETÀ ITALIANA DEI MEDICI DI MEDICINA GENERALE E DELLE CURE PRIMARIE

FARMINDUSTRIA

Egualia INDUSTRIE FARMACI ACCESSIBILI

CONFINDUSTRIA Dispositivi Medici

AIOM ASSOCIAZIONE ITALIANA ONCOLOGIA MEDICA

Società Italiana di Cardiologia — LA SOCIETÀ DELLE TRE ANIME

ISPOR Italy-Rome Chapter

Sifact SOCIETÀ ITALIANA DI FARMACIA CLINICA E TERAPIA

sihta SOCIETÀ ITALIANA DI HEALTH TECHNOLOGY ASSESSMENT

SIICA Società Italiana di Immunologia Immunologia Clinica e Allergologia

SIMeF Società Italiana di Medicina Farmaceutica Italian Society of Pharmaceutical Medicine

Sin SOCIETÀ ITALIANA DI NEUROLOGIA

SINS ITALIAN SOCIETY FOR NEUROSCIENCE

SOCIETÀ ITALIANA DI TOSSICOLOGIA SITOX 1972

Con il patrocinio di ÜNIAMO Federazione Italiana Malattie Rare Rare Diseases Italy

Banco Farmaceutico FONDAZIONE ETS

THANKS TO

turismo Torino eprovincia since 1997 Convention Bureau

Camera di commercio Torino

MEDIA PARTNER

SALUTE

SCIENTIFIC RATIONALE

A congress of a learned society serves to showcase the activities and research of the members, to imagine and shape together the future of the discipline, and to bring together professionals with similar backgrounds to allow them to establish collaborations and exchange best practices. The Congress in Turin embraces all three of these missions.

Ample space will be given, as usual, to high-quality research. Yet, there are important changes compared to the past. The traditional oral communications have been converted into topic symposia organized exclusively by the early-career pharmacology members. Furthermore, an effort has been made, whenever possible, to bring together basic and clinical content. Indeed, while **a good researcher in any discipline is measured by the ability to answer relevant scientific questions** and thus push the boundaries of knowledge, **a pharmacologist has a further challenge**: to move transversally across all areas of drug development, from target identification to market access dynamics, encompassing preclinical, non-clinical and clinical research, evidence generation and evaluation, as well as regulation and market dynamics.

The congress aims to be a showcase of the golden age we are experiencing. Drugs are being developed much more rapidly than in the past, a significantly greater number of drugs is being developed, and the available technologies have increased substantially. This new wealth is accompanied by increased complexity at every level and therefore by the need for significant changes. Proximity of care, system sustainability, telemedicine, translational medicine, precision medicine, prevention, and artificial intelligence are no longer slogans but are embedded in the pharmaceutical world we live in. In this context, the role of the pharmacologist is central, as the transversal nature of the profession will bring significant value to the system.

Finally, the congress will address many of the key cross-cutting themes at the heart of current discussions, from high-quality basic research to new tools in clinical research, from real-world evidence to regulatory uncertainties, from evidence-based medicine to the personalization of therapies, including gender pharmacology, and from economic sustainability to organizational innovation.

The congress will bring together leading experts from academia, the public and private sectors, thereby fostering a high-level and productive scientific environment. To support this process, structured networking opportunities will be provided for trainees, members serving on Ethics Committees, professionals working in Phase I Units and molecular tumor boards, and members of the SIF sections.

SCIENTIFIC CHAIR:

Armando Genazzani, Turin

SCIENTIFIC PROGRAMME COMMITTEE:

Michele Biagioli, Perugia
Mariarosaria Bucci, Naples
Annamaria De Luca, Bari
Fabrizio Gardoni, Milan
Armando Genazzani, Turin
Carla Ghelardini, Florence
Maria Antonietta Riemma, Naples
Maria Angela Sortino, Catania

EXECUTIVE COMMITTEE:

President

Armando Genazzani, Turin

Secretary

Fabrizio Gardoni, Milan

Members

Mariarosaria Bucci, Naples
Vincenzo Calderone, Pisa
Carmela Fimognari, Bologna
Ferdinando Nicoletti, Rome
Marco Pistis, Cagliari
Patrizia Popoli, Rome

President-elect

Monica DiLuca, Milan

Past President

Giuseppe Cirino, Naples

SCIENTIFIC COMMITTEE

SCIENTIFIC COMMITTEE:

Sabrina Angelini, Bologna
Maria Antonietta Barbieri, Rome
Michele Biagioli, Perugia
Mariarosaria Bucci, Naples
Annalisa Capuano, Naples
Filippo Caraci, Catania
Valerio Ciccone, Siena
Giuseppe Cirino, Naples
Massimo Collino, Turin
Annamaria De Luca, Bari
Monica DiLuca, Milan
Emanuela Esposito, Messina
Carmela Fimognari, Bologna
Matteo Fornai, Pisa
Silvana Gaetani, Rome
Fabrizio Gardoni, Milan
Armando Genazzani, Turin
Carla Ghelardini, Florence
Elena Lucarini, Florence
Alma Martelli, Pisa
Enrico Mini, Florence
Ferdinando Nicoletti, Rome
Arianna Pani, Milan
Giovanna Paolone, Verona
Marco Pistis, Cagliari
Patrizia Popoli, Rome
Maria Antonietta Riemma, Naples
Marco Andrea Riva, Milan
Adele Romano, Rome
Tiziana Rubino, Varese
Maria Angela Sortino, Catania
Gabriele Stocco, Trieste
Lara Testai, Pisa
Luigia Trabace, Foggia
Gianluca Trifirò, Verona

GENERAL INFORMATION

SCIENTIFIC SECRETARIAT

SIF Società Italiana di Farmacologia
Via Giovanni Pascoli, 3
20129 Milano - Italy
segreteria@sifweb.org
www.sifweb.org

Contacts:
M. Elena Scamoni
Adele Tangolo
Fabio Costantino

Press Office:
Rossella Gemma
Phone number: +39 328 2539028

During the Congress, SIF Organizing Secretariat will be available at the dedicated desk for any assistance or information.

ORGANIZING SECRETARIAT AND CME PROVIDER

3PSolution srl
Corso Europa, 13
20122 Milano – Italy
info@3psolution.it
www.3psolution.it

Contacts:
Chiara Ceriotti – 350 0815888
Irene Sarcina – 389 6079277
Antonella Verzelloni – 347 5856491

During the Congress, participants may contact 3P Solution Secretariat at the dedicated desk.

GENERAL INFORMATION

Congress Venue

Lingotto Conference Centre

Via Nizza, 280

10126 Turin

How to reach the Venue

The Lingotto Conference Centre is located at 280 Via Nizza, just 10 minutes away from the City Centre and Railway Stations.

Entrances to the Centre:

- **Via Nizza 280:**

Pedestrian access and drop-off entrance for private buses
Lingotto taxi drop off: www.taxitorino.it

- **Via Nizza 280 bis and Via Nizza 230:**

Entrance to underground parking (hourly and daily rates): (www.lingottoparking.com)

- **From the Sandro Pertini International Airport:**

Bus services (about 45 min.) to the Turin Porta Nuova and Turin Porta Susa railway stations, as shown on the ARRIVA website https://torino.arriva.it

Turin is also directly connected by daily bus rides from the "Malpensa 2000" Intercontinental Airport (approx. 100 km). ARRIVA https://torino.arriva.it

- **From the Turin Porta Nuova and Turin Porta Susa Railway Stations and the City Centre:**

Take Metro Line 1 toward BENGASI and exit at LINGOTTO.
Public transportation info is available from www.gtt.to.it

- **From the Turin Lingotto Railway Station:**

Use the Olympic footbridge from Lingotto Station (open **07:00**-**22:00**).

It's approximately a 20-minute walk.

- **From Motorways:**

Take Tangenziale Sud, exit at Corso Unità d'Italia and follow signs for Lingotto

GENERAL INFORMATION

Registration fees

SIF MEMBER - VAT-EXEMPT FEE

The SIF has decided to offer its MEMBERS an additional benefit.

Those who have regularly paid their membership fee can register for the Congress by paying a VAT-exempt fee (*Legal reference: "Specific fees paid by members, athletes, for institutional purposes - Outside the VAT Area - art. 4, paragraph 4, Presidential Decree 633/72"*). Please note that for VAT-exempt fee will be issued A TAX RECEIPT (Not an invoice).

SIF member	**500 €**	**300 €**
SIF member Under 38	**300 €**	**200 €**

NON-SIF MEMBER VAT INCLUDED FEE*

For VAT included fee will be issued a regular invoice.

		Day pass
NON MEMBER – Academic and Health professions	**€ 854,00 (€700 + 22% VAT)**	**€ 427,00 (€ 350 + 22% VAT)**
NON MEMBER Under 38 - Academic and Health professions and/or Member of other Scientific Societies	**€ 488,00 (€400 + 22% VAT)**	**€ 305,00 (€ 250 + 22% VAT)**
NON MEMBER - Pharmaceutical / Biotechnology Companies, Service Providers, Consultancies, Financial Institutions, Marketing & Communications Companies, Management & Data Companies and Training & Education Companies	**€ 1.159,00 (€950+ 22% VAT)**	**€ 610,00 (€ 500 + 22% VAT)**
NON MEMBER - PAYMENT WITH PAYPAL - Pharmaceutical / Biotechnology Companies, Service Providers, Consultancies, Financial Institutions, Marketing & Communications Companies, Management & Data Companies and Training & Education Companies	**€ 1.205,36 (€988 + 22% VAT)**	**€ 634,00 (€ 520 + 22% VAT)**

**On-site registration fees may be paid exclusively via PayPal.*

PROGRAMME INFORMATION

The Congress is divided into two areas:

- Continuing Medical Education (CME) Area - ROOM ROMA
- NON-CME Area

CME

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).
3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

The Congress has been accredited (ID CME 496063) with 17 CME credits with a formative technical-professional objective "Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultra-specialist activity. Rare disease", belonging to formative technical-professional objective area, for the following professions: medical doctors, pharmacists, biologists, chemists, healthcare assistants, biomedical laboratory technicians

In order to receive credits, participants must:

1. Attend at least 90% of the accredited CME sessions (attendance check);
2. **Complete the evaluation form and the CME test** by answering at least 75% of the questions correctly (in accordance with AGENAS regulations, the questionnaires will be available in the reserved area from the end of the event and may be completed until **1:00** p.m. on 1 December 2026. After this deadline, it will no longer be possible to access or complete the questionnaires and, consequently, CME credits cannot be awarded. The certificate reporting the CME credits earned will be made available online following completion of the validation process);

MY ECM

Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:

- Consult the CME events offer;
- Refer to the summary of events attended and earned credits;
- Provide an assessment of courses organized by the Provider.

To access online services please log on to https://ecm.agenas.it/professionisti-sanitari/myecm

Certificate of Attendance

The Certificate of Attendance will be available for download online after the Congress.

GUIDELINES FOR SPEAKERS

To ensure the smooth running of the programme, speakers are kindly requested to observe the following guidelines:

1. In accordance with CME regulations, **specific medicinal product brand names may not be displayed during accredited sessions**. Only generic names (active substances, instruments, devices) are permitted. **Commercial brand names must not be mentioned**, even when unrelated to the topic being presented. In addition, **references to pharmaceutical companies are not allowed**.
2. **Presentations must be submitted to the Slide Centre at least 4 hours before the session**. For sessions scheduled on 25 November 2026, presentations may be submitted up to 3 hours before the session. Presentations sent by email to the Organizing Secretariat will not be accepted.
3. **Presentations must be in PowerPoint format (.ppt/.pptx) and named according to the following convention: *SurnameName-Date*** (e.g. *RossiMario-25Nov*). Speakers are strongly advised to provide all multimedia files (videos and audio files) used in the presentation together with the PowerPoint file to ensure correct playback during the session.
4. Personal laptops cannot be connected directly to the projection system.
5. **Speakers are kindly requested to adhere strictly to the allocated presentation time**. A countdown timer will be visible during the presentation, and an audible signal will indicate when the allotted time has expired.

Technical staff will be available in each room to provide assistance.

Slide Center opening hours
Wednesday: **11.30** - **19.00**
Thursday: **08.00** - **18.00**
Friday: **08.00** - **20.00**
Saturday: **08.00** - **13.00**

Guidelines for Session Chairs

Session Chairs are kindly requested to be present in the MEETING ROOM at least 10 minutes before the start of the session and to ensure that both the session timetable and the allocated presentation times are respected.

GUIDELINES FOR POSTER PRESENTERS

At the end of the Congress, 30 prizes of €500.00 (gross) each will be awarded for the best posters. The prize will be awarded only to winners present in the room during the awards ceremony; otherwise, it will be awarded to the next eligible winner.

Presenting Authors are requested to be available during the poster discussion periods according to the official programme.

- Posters must be prepared in **English**.
- Maximum dimensions: **70 cm (W) × 100 cm (H)**.
- Posters must be displayed on the assigned numbered board.
- Posters must be removed at the end of the relevant poster session.
- Posters not removed within the scheduled time will not be stored by the Secretariat.

Poster Session I

26 November 2026 | 10:15 - 14:00

- Poster Set-Up: **10:00** - **10:15**
- Poster Display: **10:15** - **14:00**
- Discussion with the Presenting Author: **12:30** - **14:00**
- Poster Removal: **14:00** - **14:15**

Poster Session II

26 November 2026 | 15:15 – 19:00

- Poster Set-Up: **15:00** - **15:15**
- Poster Display: **15:15** - **17:30**
- Discussion with the Presenting Author: **17:30** - **19:00**
- Poster Removal: **19:00** - **19:15**

Poster Session III

27 November 2026 | 10:45 - 14:30

- Poster Set-Up: **10:30** - **10:45**
- Poster Display: **10:45** - **14:30**
- Discussion with the Presenting Author: **13:00** - **14:30**
- Poster Removal: **14:30** - **14:45**

TIMETABLE

WEDNESDAY **25 NOVEMBER 2026**

	ROOM MADRID	ROOM DUBLINO	ROOM BERLINO	ROOM LONDRA	ROOM ISTANBUL FLOOR 1	ROOM ROMA CME FLOOR 1	ROOM PARIGI FLOOR 1
13.30-14.00	Synaptic and cellular communication in neurodegeneration	Phytotherapeutics and the central nervous system	Post-marketing surveillance and appropriate drug utilization	Therapeutic drug monitoring as a measure of appropriateness in adult and pediatric populations	Precision medicine: oncology and beyond	Pharmacological innovations for the management of metabolic disorders and their comorbidities	Tissue damage and the immune microenvironment: emerging immunoregulatory mechanisms and therapeutic perspectives
14.00-14.30							
14.30-15.00							
15.00-15.30							
15.30-16.00	**AUDITORIUM OPENING CEREMONY**						
16.00-17.00	**AUDITORIUM** **Plenary Lecture: From unmet clinical needs to better care: lessons from a career in oncology research**						
17.00-18.00	**AUDITORIUM** **Plenary Round Table: Research opportunities and future perspectives in pharmacology**						
18.00-19.00	**AUDITORIUM** **Plenary Round Table: Access to therapies and early access pathways in Italy**						

TIMETABLE

THURSDAY **26 NOVEMBER 2026**

SPONSORED SESSION

	ROOM MADRID	ROOM DUBLINO	ROOM BERLINO	ROOM LONDRA	ROOM ISTANBUL FLOOR 1	ROOM ROMA CME FLOOR 1	ROOM PARIGI FLOOR 1
8.30-9.00	De novo drug design, polypharmacy, repurposing, and AI-driven discovery in rare diseases	Biotechnological drugs in modern pharmacology: emerging classes	New approaches in endothelial and cardiac dysfunction	CGRP: migraine and beyond	Pulmonary disorders: emerging targets and technologies	From visceral to somatic pain: mechanisms, pathways, and therapeutic targets	Convergent modulation of neuroinflammation and immunity through shared molecular pathways in CNS pathologies
9.00-9.30							
9.30-10.00	Preclinical and clinical research in rare disorders			Drug discovery and drug development: the role of technology transfer			
10.00-10.30			Next-generation oncology: degraders, ADCs and radioligand therapies		Precision medicine in respiratory diseases: novel biomarkers and patient stratification	Vulnerability to relapse: behavioral, circuit and molecular fingerprints	
10.30-11.00		Novel advances in cardiovascular prevention and cardiovascular disorders					Drug combinations as the modern paradigm: opportunities and challenges
11.00-11.30				Tackling antimicrobial resistance			
11.30-12.00						Modelling and simulation as drivers of innovation in pharmacology	Artificial Intelligence: the way Forward to a safe healthcare environment
12.00-12.30		Obesity and the prevention of cardiovascular risk	The disease beneath the disease: smoldering multiple sclerosis, its silent progression, and the evolving therapeutic approaches				
12.30-13.30				Institutional review board network			
12.30-14.30	POSTER SESSION 1 & LUNCH						
14.30-15.00	How precision medicine is transforming rare diseases: the avapritinib story	Prevention of infectious diseases	Cardiovascular applications of drugs used in the treatment of diabetes and obesity	Novel perspectives in eating disorders	Early diagnosis and disease-modifying strategies in Alzheimer's disease: which evidence?	Optimizing polypharmacy management in complex patients: key priorities, tools, and strategic approaches	Intestinal inflammation and tissue remodeling: from mechanisms to anti-fibrotic strategies
15.00-15.30							
15.30-16.00	Disease understanding in complement-mediated disorders: translating biology into targeted Immunopharmacology	Gene and cancer immunotherapy: unveiling molecular and cellular mechanism/s underlying immunotherapy					
16.00-16.30	Drug repurposing for neuropharmacology: translational paths from neurodevelopmental disorders to brain tumors		The evolving landscape of obesity pharmacology	The Integration of RWD and RWE into regulatory and early access processes in Italy	The social brain: from neural circuits in mice to human therapeutic insights	Chronic pain 2.0: emerging mechanisms and therapeutic strategies	The senescence - inflammation axis
16.30-17.00							
17.00-17.30							
17.30-19.00	POSTER SESSION 2						

FRIDAY **27 NOVEMBER 2026**

SPONSORED SESSION

	ROOM MADRID	ROOM DUBLINO	ROOM BERLINO	ROOM LONDRA	ROOM ISTANBUL FLOOR 1	ROOM ROMA CME FLOOR 1	ROOM PARIGI FLOOR 1
8.30-9.00	At the crossroads of eating disorders and addictive behaviors: converging mechanisms towards translational perspective	Natural compounds and barrier functions: new evidence between gastroprotection, metabolism, and aging	Drug targeting of cancer cells	Novel and 3R-compliant platforms for early translational research in rare diseases	The metastatic partnership: vascular, stromal and immune interaction in the journey of circulating tumor cells	Role of sex differences in the modulation of lipid-derived mediators across different pathological conditions	Deconstructing neurodevelopmental disorders: from neurobiological mechanisms to clinical trials
9.00-9.30							
9.30-10.00	Bispecific antibodies: from the laboratory to the clinic				Pharmacogenetics in personalized medicine	Psychedelics and more: innovative treatments for neurodevelopmental diseases and therapeutic challenges	
10.00-10.30		The next generation of clinical pharmacology and hospital pharmacy: contributions from specialty trainees	Emerging strategies in cardiovascular prevention	Transitional care in rare diseases: regulatory and therapeutic pathways for orphan drugs and advanced therapies			
10.30-11.00							
11.00-11.30					The role of pharmacology in clinical precision oncology	From maternal well-being to offspring mental health: molecular determinants of intergenerational vulnerability	Marine Pharmacology: a sea of opportunities
11.30-12.00	CAR-T: precision mechanisms and therapeutic innovation	Medicines in the environment: monitoring, treatments and intervention strategies	**SIF-EGUALIA Symposium** From generic and biosimilar medicines to essential medicines: new scientific and industrial challenges to ensure access to healthcare in Europe	Givinostat in Duchenne muscular dystrophy: an Italian story of scientific innovation, translational research and patient partnership			
12.00-12.30				Beyond individual syndromes: how should the regulatory approach to DEEs evolve			
12.30-13.30	**POSTER SESSION 3 & LUNCH**						Molecular Tumor Board Network
13.30-14.30	**POSTER SESSION 3 & LUNCH**						Phase I Clinical Trial Network
14.30-15.00	Dyshomeostasis of non-neuronal cells as a novel and early pharmacological target in neurodegenerative disorders	Rare tumors: management of unmet medical needs	**SIF-FARMINDUSTRIA Symposium** Clinical pharmacology and the competitiveness of the Italian system: between global pressures and national regulatory choices	Safety and regulatory framework for medicinal plants and nutraceutical	Teaching 2.0: innovative methodological approaches	Therapeutic advances in developmental and epileptic encephalopathies: present and future	Sex-aware pharmacological research: from scientific evidence to experimental practice
15.00-15.30							
15.30-16.00		Unlocking Transient Receptor Potential (TRP) channels		Assembly of the SIF Early Career Pharmacology Group			
16.00-16.30			Assembly of the SIF Clinical Pharmacology Section				Assembly of the SIF Education Section
16.30-17.30	**AUDITORIUM** Case studies of industrial research and development						
17.30-18.00	**AUDITORIUM** Beyond words: when emotions become movement						
18.00-20.00	**AUDITORIUM SIF GENERAL ASSEMBLY**						

SATURDAY **28 NOVEMBER 2026**

	ROOM MADRID	ROOM DUBLINO	ROOM BERLINO	ROOM LONDRA	ROOM ISTANBUL FLOOR 1	ROOM ROMA CME FLOOR 1	ROOM PARIGI FLOOR 1
8.30-9.00	Advances in alternative research methods	Frailty in complex comorbidities	**Joint SIF–SIICA Symposium:** targeting immunometabolism Young investigators rewiring immune function	Targeting cellular and structural components of the tumor microenvironment	Real-world evidence of biologic drugs in immune mediated inflammatory diseases	Environmental stress as a driver of neuro-immuno-metabolic disease: risk factors and vulnerability mechanisms	Substance use disorders in adolescence and adulthood: neurobiological adaptations, behavioral outcomes, and their clinical relevance
9.00-9.30							
9.30-10.00		Intestinal microbiota in extra-digestive disorders			Stress across the lifespan: mechanistic insights		
10.00-10.30	Managing uncertainty and non-traditional outcomes in drug approval and reimbursement		Inflammation and response to pharmacological treatment in psychiatric disorders	Clinical pharmacology and the National Health System		Biological therapies and molecular target drugs in chronic inflammatory autoimmune diseases: from basic and translational research to clinical evidence	Post-transcriptional regulation: the molecular interface between health and disease
10.30-11.00					In-training clinical pharmacologists/toxicologists and hospital pharmacists: the SIF Contest		
11.00-11.30							
11.30-12.30	**AUDITORIUM** EPHAR Lecture: Lysosomal calcium signalling: from discovery to the clinic						
12.30-13.00	**AUDITORIUM** Conclusions and Awards						

SCIENTIFIC PROGRAMME

Continuing Medical Education (CME) Area

ROOM ROMA

25 November 2026

13.30 – 15.30

Pharmacological innovations for the management of metabolic disorders and their comorbidities

Chairpersons: **Marzia Friuli, Laura Rizzi**

13.30 Targeting the liver-brain axis in diabesity-associated Alzheimer's disease: hepatic NLRP3 as a pharmacological node
Claudio Pirozzi

13.45 Impact of ANGPTL3-targeted therapies on lipids and apolipoproteins: a meta-analysis of randomized controlled trials
Elena Olmastroni

14.00 Beyond the trip: the metabolic action of psilocybin in steatotic liver disease
Anna Signor

14.15 Competing risk of death and neurological outcomes in elderly diabetic patients treated with GLP-1 receptor agonists
Vera Battini

14.30 Effects of N-acylethanolamines on obesity-induced cardiometabolic alterations
Nicol Pia Navatti

14.45 Pharmacological modulation of the paracannabinoid system in diet-induced overweight: insights into early cardiac dysfunction
Alessia Campagna

15.00 Cholinergic stimulation promotes resilience and PD-L1 expression in human terminally differentiated β-cells: implications for novel Type 1 Diabetes strategies
Francesco Petragnano

15.15 Adolescent high-fat diet programs a lipotoxic and bioenergetically inefficient skeletal muscle phenotype: protective role of oleoylethanolamide
Christian Sepe

26 November 2026

08.30 – 10.00

From visceral to somatic pain: mechanisms, pathways, and therapeutic targets

Chairpersons: **Stefania Ceruti, Andrea Maria Morace**

08.30 µ-opioid receptor in NK cells as a potential biomarker for neuropathic pain: evidence from the CCI model and modulation by bergamot polyphenolic fraction
Lucia Carmela Passacatini

08.45 Decoding vulvodynia: from pelvic sensitivity to central pain processing
Michela Perrone

09.00 Exploring the dual role of *Mangifera indica* L. in alleviating abdominal visceral pain and inflammation
Anna Schettino

09.15 Dissecting the gut–vulva axis: translational insights from IBS-associated vulvodynia and evaluation of glucosinolates-based therapy
Elena Lucarini

09.30 From intestinal epithelium to visceral pain: molecular mechanisms involved in IBS
Sofia Faggin

09.45 Dissecting MOR-CB1 interactions in neuronal cell models: implications for opioid-cannabinoid co-treatment in chronic pain
Gaia Lusoli

10.00 – 11.30

Vulnerability to relapse: behavioral, circuit and molecular fingerprints

Chairpersons: **Roberto Ciccocioppo, Fabio Fumagalli**

10.00 Cocaine withdrawal during adolescence alters hippocampal neuro-glia interaction dynamics and excitatory–inhibitory synapses in response to an acute stress
Lucia Caffino

10.20 Impact of adolescent social exclusion on relapse susceptibility to alcohol seeking and stress-related behaviors in male and female rats
Esi Domi

10.40 Dorsal raphe projections to the central amygdala and nucleus accumbens drive methamphetamine relapse
Daniele Caprioli

11.00 Multidimensional addiction profiling in outbred rats: from individual differences to medication development
Paola Campo

11.30 – 12.30

Modelling and simulation as drivers of innovation in pharmacology

Chairpersons: **Carla Ghelardini, Gianluca Miglio**

11.30 From data to model
Oscar Della Pasqua

11.45 From mechanistic knowledge to translational impact: a systems biology and QSP perspective
Enrico Domenici

12.00 Regulatory impact of PK and PD modelling and simulation: expectations and practical cases
Serena Zamponi

12.15 Novel approaches to Hypoparathyroidism
Maria Luisa Brandi

14.30 – 16.00

Optimizing polypharmacy management in complex patients: key priorities, tools, and strategic approaches

Chairpersons: **Romano Danesi, Amelia Filippelli**

14.30 Medication reviews and pharmacogenetics: the critical role of data integration
Valeria Conti

14.45 Medication review in different care settings, constraints and potential benefits
Elisabetta Poluzzi

15.00 Artificial Intelligence in medication review and deprescribing services
Gianluca Trifirò

15.15 Clinical assessment of drug–drug interactions: insights from a national pilot study
Riccardo Giossi

15.30 AIFA's Position Paper on the implementation of precision medicine
Robert Nisticò

16.00 – 17.30

Chronic pain 2.0: emerging mechanisms and therapeutic strategies

Chairpersons: **Laura Micheli, Paola Sacerdote**

16.00 Emerging strategies for pain management in Fabry Disease, a rare genetic disorder
Silvia Franchi

16.15 Proteome-wide characterization of neuroinflammatory signatures in morphine-exposed spinal tissue: modulation by ultramicronized palmitoylethanolamide
Alessandra Toti

16.30 Effect of conditioned diet in a model of early life-induced widespread pain: potential role of HCAR2 receptors
Carmela Belardo

16.45 Neuroinflammatory mechanisms in opioid-related side effects
Laura Rullo

17.00 NanoBEO: transdermal nanotechnology for the management of pain and agitation in severe dementia
Damiana Scuteri

27 November 2026

08.30 – 09.30

Role of sex differences in the modulation of lipid-derived mediators across different pathological conditions

Chairpersons: **Vincenzo Brancaleone, Simona Pace**

08.30 Dysfunctional gut microbiota–endocannabinoid axis exacerbates skeletal muscle and brain deficits in Duchenne muscular dystrophy (DMD)
Noemi Di Muraglia

08.45 Sex-dependent modulation of audiogenic seizures by ketogenic diet in a GluN2A(N615S) model of GRIN-related encephalopathy
Alessandra Lodi

09.00 Sex-specific lipid mediator profile drives pulmonary fibrosis pathogenesis in mice
Danilo D'Avino

09.15 Sex-specific pharmacotherapy and vascular stiffness in hypertension
Marialuisa Sveva Marozzi

09.30 – 11.00

Psychedelics and more: innovative treatments for neurodevelopmental diseases and therapeutic challenges

Chairperson: **Riccardo Brambilla**

09.30 Sex dependent behavioral and brain molecular effects of psilocybin in mice exposed to early life stress
Laura Musazzi

09.50 Psilocybin in neurodevelopmental disorders: preclinical insights into mechanisms of action
Viviana Trezza

10.10 Cortico-striatal pathophysiology for neurodevelopmental disorders associated with 16p11.2 CNVs: implications for therapeutic targeting
Ilaria Maria Morella

10.30 SHANK3 related autism: from cell biology to new treatment opportunities
Zaira Tomasoni

11.00 – 12.30

From maternal well-being to offspring mental health: molecular determinants of intergenerational vulnerability

Chairpersons: **Miriam Melis, Marco Andrea Riva**

11.00 Functional and molecular insights linking maternal stress across pregnancy to offspring vulnerability
Alessia Marchesin

11.15 Fueling vulnerability: mitochondrial control of dopamine circuits after developmental cannabis exposure
Federico Brandalise

11.30 Preconception social stress: from placental adaptations to lifelong behavioral outcomes
Juliet Richetto

11.45 Postpartum alcohol exposure reorganizes the maternal brain network to disrupt caregiving behavior
Sebastiano Bariselli

12.00 Deciphering the role of IL-17A in ASD-like phenotypes: evidence from a maternal immune activation mouse model
Anna Maria Tartaglione

12.15 Sex-divergent effects of cannabidivarin treatment in rats prenatally exposed to VPA
Erica Zamberletti

14.30 – 15.40

Therapeutic advances in developmental and epileptic encephalopathies: present and future

Chairpersons: **Emilio Russo, Maurizio Taglialatela**

14.30 From genotype-phenotype correlations to emerging therapeutic strategies in SCN1A-related neurological disorders
Paola Imbrici

14.50 Gut Microbiota in Angelman Syndrome: toward biomarkers and novel therapeutic strategies
Carmen De Caro

15.10 Investigating sex differences in a validated model of GRIN2A-related DEE: psychopathological and therapeutic implications
Ilaria Bertocchi

15.20 Targeted therapies in KCNQ2-related developmental and epileptic encephalopathies
Francesco Miceli

28 November 2026

08.30 – 10.00

Environmental stress as a driver of neuro-immuno-metabolic disease: risk factors and vulnerability mechanisms

Chairpersons: **Adriano Lama, Davor Virag**

08.30 RACK1 modulation as a mechanistic platform for screening immunotoxic effects of endocrine disrupting chemicals
Mirco Masi

08.45 Environmental chemicals as drivers of neuronal vulnerability: glutamatergic receptor dynamics in critical developmental windows
Melania Maria Serafini

09.00 Nanoplastic co-exposure as an emerging environmental driver of metabolic dysfunction in liver and adipose tissue
Stefania Melini

09.15 Downregulation of Kv7 channels contributes to angiotensin-II induced modulation of neuronal activity in brain areas controlling sympathetic tone
Stefania Iervolino

09.30 Invisible invaders: subacute nanoplastic ingestion drives neuroinflammation via the gut-brain axis
Federico Ciceri

09.45 Early life stress alters hypothalamic-peripheral metabolic signaling linking psychiatric and metabolic vulnerability
Ilari D'Aprile

10.00 – 11.30

Biological therapies and molecular target drugs in chronic inflammatory autoimmune diseases: from basic and translational research to clinical evidence

Chairpersons: **Massimo Collino, Ciriana Orabona**

10.00 A new frontier in IL-17 antagonism: FM15TM, a first-in-class linear small peptide with translational potential in chronic inflammation and autoimmune diseases
Francesco Maione

10.20 Reframing IMIDs: the IL-23 pathway from mechanisms to pharmacological perspectives
Luca Antonioli

10.40 Novel imaging-based methods for validating immunopharmacology *in vivo*
Ishii Masaru

11.00 International recommendations for the management of rheumatoid arthritis and psoriatic arthritis with pharmacological therapies
Annamaria Iagnocco

SCIENTIFIC PROGRAMME

NON CME AREA

25 November 2026

AUDITORIUM

15.30 – 16.00 Opening Ceremony
Paola Cassoni, Vicerettrice Università degli Studi di Torino
Robert Nisticò, Presidente Agenzia Italiana del Farmaco

16.00 – 17.00 Plenary Lecture
From unmet clinical needs to better care: lessons from a career in oncology research
Introduced by **Armando Genazzani**
Speaker: **Lucia Del Mastro**

17.00 – 18.00 Plenary Round Table
Research opportunities and future perspectives in pharmacology
Chairpersons: **Giuseppe Cirino, Monica DiLuca**
Participants: **Roberto Di Lauro, Gaetano Guglielmi**

18.00 – 19.00 Plenary Round Table
Access to therapies and early access pathways in Italy
Chairperson: **Armando Genazzani**
Participants: **Massimo Di Maio, Andrea Marcellusi, Robert Nisticò, Annalisa Scopinaro**

ROOM MADRID

13.30 – 15.30
Synaptic and cellular communication in neurodegeneration
Chairpersons: **Roberta Facchinetti, Giulia Sita**

13.30 Co-ultramicronized palmitoylethanolamide/luteolin inhibits astrocyte-mediated oligodendrocyte dysfunction in an *in vitro* model of β-amyloid toxicity
Claudia Ciarla

13.45 Targeting lysosomal dysfunction via a GTD-released GCase modulators in GBA1 and Grn mouse models
Chiara Bertasini

14.00 Ca^{2+}-storing organelles as druggable targets in astrocyte-neuron communication during Alzheimer's disease progression
Silvia Piccirillo

14.15 Purple corn anthocyanins protect against the progression of multiple sclerosis and associated trigeminal pain reducing glial activation
Benedetta Riboldi

14.30 Investigating glymphatic dysfunction in persistent pain: AQP4 downregulation and CSF flow alteration in a mouse model of oxaliplatin-induced neuropathy
Clara Ciampi

14.45 Astroglial endoplasmic reticulum-mitochondria interaction as a possible target for Alzheimer's disease treatment
Giulia Dematteis

15.00 Deciphering the role of CAP2 in neuronal mitochondrial vulnerability in Alzheimer's disease
Ramona Stringhi

15.15 Cellular Prion Protein (PrPc) and TGFβ1-receptors antagonistically settle microglial activity in response to tau oligomers
Giorgia Serena Gullotta

ROOM DUBLINO

13.30 – 15.30
Phytotherapeutics and the central nervous system
Chairpersons: **Vittoria Borgonetti, Antonella Di Sotto**

13.30 Neurological adverse reactions associated with cannabis-derived products
Ilaria Ammendolia

13.45 Retinal protective effects of cannabidiol in an *in vivo* model of AMPA-induced excitotoxicity
Federica Conti

14.00 From pain to relief: plasma cannabinoid levels in patients using cannabis oil extracts
Alessandra Manca

14.15 Association of *Commiphora myrrha* extract and cannabidiol: combined stimulation of the opioid and cannabinoid system for the treatment of neuropathic pain
Samuele Trisolini

14.30 Neuroimmune modulation by chronic ellagic acid administration in EAE mice: bridging noradrenergic system and synaptic pruning
Veronica Torre

14.45 Ellagic acid-loaded nanovesicles rescue LTP impairment and neuroinflammation in an AD *ex-vivo* model
Nunzia Maisto

15.00 Genetic deletion of Kv7.5 channel impairs the blood-brain barrier, enhances seizure susceptibility, and abolishes the anticonvulsant effect of the rosemary-derived small molecule carnosic acid
Camilla Celentano

15.15 Early chronic low-dose psilocybin promotes visual cortex plasticity and functional recovery after occipital stroke
Sofia Nasini

ROOM BERLINO

13.30 – 15.30
Post-marketing surveillance and appropriate drug utilization
Chairpersons: **Maria Antonietta Barbieri, Salvatore Crisafulli**

13.30 Assigning Defined Daily Dose (DDD) to ophthalmological antibiotics (ATC S01AA): Why is it challenging? Why is it important?
Angela Boccia

13.45 Real-World Effectiveness and safety of DOACs vs VKAs according to anticoagulation quality in patients with atrial fibrillation and cancer: toward appropriate anticoagulant selection
Gianluca Gazzaniga

14.00 Therapeutic switching and prescribing appropriateness in pregnancy: a retrospective study from the PERSONA project
Giada Crescioli

14.15 Neuropsychiatric adverse events with Anti-IL17 approved for plaque psoriasis: an analysis from the Food and Drug Administration adverse event monitoring system
Giulia Russo

14.30 Assessing the safety of pediatric biologics using a multi-step signal detection approach: a VigiBase study
Nicoletta Luxi

14.45 Neuropsychiatric disorders during treatment for ADHD with atomoxetine and methylphenidate: a systematic review and meta-analysis of randomised controlled trials
Raffaella Di Napoli

15.00 Polypharmacy and potential drug misuse in patients with type 2 diabetes mellitus: a Swedish register-based drug utilization study
Antonietta Anatriello

15.15 Implementation and impact of pharmacogenetics, therapeutic drug monitoring and medication review on optimizing therapy effectiveness and mitigating adverse drug reactions in pediatric patients
Paolo Dalla Zuanna

ROOM LONDRA

13.30 – 15.30
Therapeutic drug monitoring as a measure of appropriateness in adult and pediatric populations
Chairpersons: **Bianca Maria Goffredo, Marianna Lucafò**

13.30 A new optimized *in-silico* deferasirox dose rationale for the treatment of iron overload in pediatric patients undergoing haematopoietic stem cell transplantation
Giammarco Baiardi

13.45 Optimal plasma cut-off value of active Anti-Thymocyte Globulin (ATG) to prevent aGVHD and the role of miRNA320 in pediatric HSCT recipients
Debora Curci

14.00 Saliva-based therapeutic drug monitoring of antiseizure medications: a non-invasive approach in Lennox-Gastaut Syndrome
Francesca Dattrino

14.15 Plasma cannabidiol concentrations in real-world clinical practice: impact of dose and concomitant antiseizure medications
Alessia Cafaro

14.30 Use of PK/PD modeling techniques for the optimization and personalization of antibiotic therapy in critically ill pediatric patients undergoing extracorporeal purification techniques
Raffaele Simeoli

14.45 Plasma concentration profile of ropivacaine in arterial blood following erector spinae plane block in thoracic and cardiac surgical procedures
Alice Palermiti

15.00 Optimizing vancomycin dosing in non-critically ill patients: PK/PD target attainment and development of a renal function–based dosing nomogram
Francesco Russiani

15.15 Integrated CYP3A4 and CYP3A5 genotyping enables precision tacrolimus dosing in kidney transplant recipients
Michelangelo Rottura

ROOM ISTANBUL

13.30 – 15.30

Precision medicine: oncology and beyond

Chairpersons: **Gloria Ravegnini, Rossana Roncato**

13.30 Peripheral biomarkers to support a personalized approach in severe mental disorders
Anna Meloni

13.45 Gut microbiota-driven modulation of thiopurine response: towards precision medicine in IBD
Martina Franzin

14.00 Revealing sex-specific treatment outcomes and molecular signatures in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy: implications for personalized therapy
Noemi Milan

14.15 Optimizing DPYD pharmacogenetics: from variant-specific dosing to haplotype-based risk stratification
Martina Gambron

14.30 UGT1A1*28 polymorphism does not predict neuropsychiatric drug toxicity in HIV-positive patients
Emanuela De Bellis

14.45 Optimizing precision medicine in FLT3-mutated acute myeloid leukemia: translational safety evaluation of FLT3 inhibitors through meta-analysis and real-world pharmacovigilance
Cecilia Cagnotta

15.00 Originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials
Consiglia Riccardi

15.15 Toward personalized imatinib therapy in GIST: sex differences and the clinical value of therapeutic drug monitoring in a real-world Italian cohort
Eleonora Cecchin

ROOM PARIGI

13.30 – 15.00

Tissue damage and the immune microenvironment: emerging immunoregulatory mechanisms and therapeutic perspectives

Chairpersons: **Massimo Collino, Benedetta Pieroni**

13.30 Targeting the H_2S–FPR2 axis: an emerging immunoregulatory mechanism in tissue damage and inflammation resolution
Ludovica Lela

13.45 Blueprint mapping reveals a therapeutic window for topical anti-IL-17A/F monoclonal antibodies targeting the psoriatic immune microenvironment
Anella Saviano

14.00 NR2F6: a novel immunoregulatory node linking tissue microenvironment and immune activation
Giorgia Manni

14.15 Gut-directed NLRP3 blockade limits systemic tissue damage and restores function in a model of aging-related decline
Giulia Valdiserra

14.30 Targeting αMβ2 integrin to reprogram immune cell function: from inflammation to tumor microenvironment remodelling
Andrea Maurizio

14.45 Long intergenic non-coding RNA-p21 in juvenile idiopathic arthritis: a novel mediator and biomarker of methotrexate response
Federico Riccardi

26 November 2026

POSTER SESSIONS

12.30 – 14.00 POSTER SESSION 1
17.30 – 19.00 POSTER SESSION 2

ROOM MADRID

08.30 – 09.30
De novo drug design, polypharmacy, repurposing, and AI-driven discovery in rare diseases
Chairpersons: **Giorgia Dinoi, Andrea Tarozzi**

08.30 Drug repurposing in pediatric rare diseases: a retrospective analysis of off-label prescriptions at the University Hospital of Catania
Giorgia Loreto

08.45 Integration of genome-wide association, bioinformatics, and machine learning studies for drug repurposing in Huntington's disease
Barbara Pagliarani

09.00 The p.L689F mutation of Nav1.4 sodium channel in myotonia permanens: a functional and pharmacological study
Paola Laghetti

09.15 Bridging *in silico* and *in vitro* approaches to identify Kv1.1 and Kv1.2 potassium channels modulators for associated neurological disorders
Alessandro Giovanni Cerchiara

09.30 – 12.30
Preclinical and clinical research in rare disorders
Chairpersons: **Enrico Costa, Annamaria De Luca**

09.30 Uncovering REST as a prognostic factor and therapeutic target in ALS
Luigi Formisano

10.00 Bridging preclinical research and clinical evidence for use of SGLT2 inhibitors in Lafora Disease
Antonella Liantonio

10.30 Adaptive clinical trial design and RWE: how to overcome evidence gap in rare disease research
Gianluca Trifirò

11.00 TK2d: optimizing patient pathways through early recognition, differential diagnosis and multidisciplinary management
Caterina Garone

11.30 Clinical research in rare primary immunodeficiencies: from study design to drug approval
Cinzia Milito

12.00 X-linked Adrenoleukodystrophy (X-ALD): pathophysiology and pharmacological aspects
Anna Ardissone

SPONSORED SESSION** blueprint MEDICINES a sanofi company

14.30 – 15.30

How precision medicine is transforming rare diseases: the avapritinib story

Simone Baldovino, Armando Genazzani, Massimo Triggiani

SPONSORED SESSION sobi

15.30-16.00

Disease understanding in complement-mediated disorders: translating biology into targeted Immunopharmacology

Chairperson: **Valentina Drago**

Speaker: **Carlo Riccardi**

16.00 – 17.30

Drug repurposing for neuropharmacology: translational paths from neurodevelopmental disorders to brain tumors

Chairpersons: **Emanuela Esposito, Gabriele Stocco**

16.00 Identification of a novel Kv7 opener for epilepsy treatment: challenges and opportunities
Maurizio Taglialatela

16.20 Crossing boundaries: a fly avatar platform for high-throughput cancer drug repurposing in ASD
Claudia Bagni

16.40 Drug repositioning strategy for Spinal Muscular Atrophy
Marina Boido

17.00 Key role of preclinical studies in repurposing strategies for complex rare disorders: lessons from neuromuscular diseases
Brigida Boccanegra

ROOM DUBLINO

08.30 – 10.00

Biotechnological drugs in modern pharmacology: emerging classes

Chairpersons: **Maria Antonietta Barbieri, Valerio Ciccone**

08.30 Emerging RNA therapeutics: miR-22 inhibition for the treatment of neuropathic pain
Francesco Margiotta

08.45 Drugging the "undruggable": rewiring cancer through transcription factors degraders
Sara Boumya

09.00 Modulation of the immune landscape of chronic rhinosinusitis with nasal polyps
Benedetta Romano

09.15 The potential of near-infrared photobiomodulation in assisted reproduction: effects on sperm motility and oocyte maturation
Matilde Balbi

09.30 Exploring gene editing tools for astrocyte-specific therapy in Alexander disease
Irene Capuano

09.45 Strategies to counteract olipudase alfa allergy
Federico Spataro

10.30 – 12.00

Novel advances in cardiovascular prevention and cardiovascular disorders**

Chairpersons: **Alma Martelli, Danilo Norata**

10.30 New approaches for the treatment of dyslipidemia
Alberto Corsini

10.50 Targeting Lipoprotein(a): current and emerging therapeutic strategies for cardiovascular prevention
Francesca Zimetti

11.10 Immune dysregulation in cardiovascular disease - from novel mechanisms to therapeutic targeting
Pasquale Maffia

11.30 Recent advances in pulmonary hypertension
Claudia Raineri

SPONSORED SESSION novo

12.00 – 12.30

Obesity and the prevention of cardiovascular risk

Armando Genazzani, Pasquale Perrone Filardi

14.30 – 15.30

Prevention of infectious diseases

Chairpersons: **Giovanni Di Perri, Francesco Scaglione**

14.30 Pre-Exposure Prophylaxis (PrEP) in HIV
Giordano Madeddu

14.50 RSV vaccination
Fabrizio Bert

15.10 Vaccination in oncological patients
Valentina Bertaglia

15.30 – 17.10

Gene and cancer immunotherapy: unveiling molecular and cellular mechanism/s underlying immunotherapy

Chairpersons: **Vincenzo Brancaleone, Stefania Marzocco**

15.30 Reprogramming immune reactivity: the role of cell-specific metabolic genes in the tumor microenvironment
Francesca Fallarino

15.50 Multi-omic profiling of the tumor ecosystem to unveil molecular and cellular mechanisms underlying immunotherapy
Rosalinda Sorrentino

16.10 Insight into the relevance of cell-autonomous innate immunity in gene therapy
TBD

16.30 Harnessing immune mechanisms to address unmet clinical needs in nasopharyngeal carcinoma
Romano Danesi

16.50 Innate lymphoid cells: a new frontier in cancer immunotherapy
Giuseppe Ercolano

ROOM BERLINO

08.30 – 10.00

New approaches in endothelial and cardiac dysfunction

Chairpersons: **Valerio Ciccone, Lorenzo Da Dalt**

08.30 Preclinical evaluation of novel molecules in endothelial dysfunction: profile of VEGF-mimetic peptides QK and HPLW-2
Arianna Filippelli

08.45 Pharmacological treatments in patients with transthyretin cardiac amyloidosis: a systematic review and meta-analysis
Eugenia Piragine

09.00 Doxorubicin-induced inflammatory injury: simvastatin as a potential cardioprotective agent
Roberta Vitale

09.15 eNOS hyper-persulfidation accounts for diabetes-associated vascular dysfunction
Martina Smimmo

09.30 Mechanistic insights into norbormide-induced cardiovascular toxicity in rats
Alessia Bichicchi

09.45 Stress granules as mediators of cardiac damage by dysfunctional HDL during acute coronary syndrome
Chiara Oliviero

10.00 – 12.00

Next-generation oncology: degraders, ADCs and radioligand therapies

Chairpersons: **Fabrizio Condorelli, Ambra Grolla, Cristina Travelli**

10.00 Degraders: beyond the conventional inhibition-based strategies
Ambra Grolla

10.20 Radioligand therapies: emerging frontiers in precision oncology
TBD

10.40 The revolution of ADCs
Armando Genazzani

11.00 The use of network meta-analyses for indirect treatment comparisons: the example of multiple myeloma
Carlotta Galeone

11.30 Next-generation antibody–drug conjugates: design, mechanisms and emerging perspectives
Romano Danesi

SPONSORED SESSION** sanofi

12.00 – 12.30

The disease beneath the disease: smoldering multiple sclerosis, its silent progression, and the evolving therapeutic approaches
Marinella Clerico

14.30 – 16.00

Cardiovascular applications of drugs used in the treatment of diabetes and obesity**

Chairpersons: **Alma Martelli, Francesco Rossi**

14.30 Vascular effects of GLP-1 and other incretin mimetics
Elena Osto

14.50 Exploiting the cardiovascular properties of "classical" antidiabetics: from "old" metformin to new metformin-based chemical entities
Vincenzo Calderone

15.10 Evidence for the benefits of combining dapagliflozin with sacubitril/valsartan in cardiometabolic and age-related cardiac dysfunction
Antonella De Angelis

15.30 cAMP/CREB/CSE axis accounts for the beneficial effect of dapagliflozin in cardiometabolic HFpEF
Valentina Vellecco

WITH THE UNRESTRICTED GRANT OF Lilly A MEDICINE COMPANY

16.00 – 17.30

The evolving landscape of obesity pharmacology

Chairpersons: **Silvana Gaetani, Valentina Vellecco**

16.00 The evolution of obesity pharmacology beyond incretins
Thomas Lutz

16.20 Amylin and oleoylethanolamide at the interface of satiation and satiety: a multi-target strategy for obesity pharmacotherapy
Adele Romano

16.40 Incretins at the interface of prandial lipid metabolism and inflammation
Andrea Baragetti

17.00 Beyond weight loss: dual GLP-1/glucagon agonists as disease-modifying therapy in MASLD
Matteo Monami

ROOM LONDRA

08.30 – 09.30

CGRP (Calcitonin Gene-Related Peptide): migraine and beyond

Chairpersons: **Cristina Benatti, Luigi Francesco Iannone**

08.30 Study of effect of rimegepant in a murine model of endometriosis and migraine comorbidity
Chiara Sturaro

08.45 How anti-CGRP strategies reshape the overall migraine experience in Real-World Responders
Antonio Munafò

09.00 Age- and sex-dependent differences in sumatriptan responsiveness in a CGRP-induced mouse model of migraine-like photophobia
Veronica Rivi

09.15 Baseline Leeds Dependence Questionnaire scores are not associated with medication overuse persistence under anti-CGRP therapy in chronic migraine with medication-overuse headache
Andrea Burgalassi

09.30 – 11.00 ROUND TABLE

Drug discovery and drug development: the role of technology transfer

Chairpersons: **Pier Luigi Canonico, Giulio Pompilio**

Participants: **Filippo Caraci, Monica DiLuca, Beatrice Riva, Silvia Rossi, Laura Spinardi, Giuseppe Toffoli**

11.00 –12.30

Tackling antimicrobial resistance

Chairpersons: **Elisabetta Bigagli, Federico Pea**

11.00 Tackling antimicrobial resistance with new BL/BLI in treating Gram-negative infections
Milo Gatti

11.20 Tackling antimicrobial resistance with new long-acting antibiotics in treating Gram-positive infections
Dario Cattaneo

11.40 Antimicrobial resistance in pediatric infections: epidemiological scenarios and implications for antimicrobial stewardship
Stefania Nobili

12.00 New insights into pediatric infectious diseases: antibiotics, artificial intelligence and one-health approach
Silvia Garazzino

12.30-13.30

Institutional review board network

Jacopo Angelini, Francesco Rossi

12.30 Introduzione e sintesi del documento
Francesco Rossi, Jacopo Angelini:

12.40 Focus EAP: Il punto di vista di AIFA
Sandra Petraglia

12.50 Focus EAP: Il punto di vista dei clinici
Rossana Berardi

13.00 Focus EAP: Il punto di vista dei CE
Annalisa Capuano

13.10 Discussione con domande dai partecipanti

14.30-16.00

Novel perspectives in eating disorders

Chairpersons: **Paola Fadda, Maria Vittoria Micioni Di Bonaventura**

14.30 Unraveling neurodevelopmental dysregulation in anorexia nervosa: insights from multi-omics
Claudio D'Addario

14.50 Targeting epigenetic pathways in compulsive eating: entinostat produces lasting suppression of binge episodes in a rodent model
Giacomo Einaudi

15.10 The neurobiology of anorexia nervosa: connectivity patterns, neurochemical gradients, and their clinical correlates
Enrico Collantoni

15.30 Beyond the brain: peripheral epigenetic regulation of muscle dysfunction in binge eating disorders and therapeutic opportunities
Elena Conte

16.00-17.30 ROUND TABLE

The Integration of RWD and RWE into regulatory and early access processes in Italy

Chairpersons: **Valentina Drago, Gianluca Trifirò**

Participants: **Mariangela Amoroso, Salvatore Crisafulli, Nello Martini, Francesca Patarnello, Sandra Petraglia, Patrizia Popoli**

ROOM ISTANBUL

08.30 – 10.00

Pulmonary disorders: emerging targets and technologies

Chairpersons: **Ida Cerqua, Giuseppe Spaziano**

08.30 Time course disease monitoring with computed tomography imaging: enhancing translational research from bench to bedside
Elena Mantovani

08.45 When smoke meets nanoplastics: a new driver of airway inflammation and COPD progression
Davida Mirra

09.00 Targeting CD105: inhaled siRNA therapy for pulmonary fibrosis
Erika Esposito

09.15 An innovative label-free approach for investigating epithelial-mesenchymal transition: pharmacological characterization of TGF-β1 effects in A549 cells
Francine Medjiofack Djeujo

09.30 From environment to epithelium: biological and clinical effects of indoor and outdoor pollution in Campania's schoolchildren
Martina Simonelli

09.45 Effect of a newly approved treatment for cystic fibrosis on cardiovascular-related serum lipoprotein functions
Marcella Palumbo

10.00 – 12.00

Precision medicine in respiratory diseases: novel biomarkers and patient stratification

Chairpersons: **Luca Gallelli, Antonietta Rossi**

10.00 Biomarkers and artificial intelligence in precision medicine: new frontiers in asthma, COPD and ILD
Mario Salvatore Clerici

10.20 Sex-specific epigenetic mechanisms in respiratory diseases: from biomarkers to therapeutic opportunities
Fiorentina Roviezzo

10.40 Severe asthma and Type 2 inflammation: current biologics and emerging therapeutic targets
Vincenzo Patella

11.00 Pulmonary fibrosis and Raynaud's Phenomenon: early diagnosis and novel antifibrotic strategies
Barbara Ruaro

11.20 New mechanisms of action in pulmonary fibrosis: from disease biology to therapeutic innovation
Martina Bonifazi

WITH THE UNRESTRICTED GRANT OF Lilly A MEDICINE COMPANY

14.30-16.00

Early diagnosis and disease-modifying strategies in Alzheimer's disease: which evidence?

Chairpersons: **Marco Bozzali, Filippo Caraci**

14.30 Evolution of Alzheimer's disease biomarkers
Cristina Lanni

14.50 Targeting amyloid in Alzheimer's disease: pharmacological profile of monoclonal antibodies
Elena Marcello

15.10 The role of biomarkers in the diagnostic pathway for Alzheimer's disease
Alberto Benussi

15.30 Passive immunotherapy in Alzheimer's disease: novel clinical evidence
Federica Agosta

16.00 – 17.30

The social brain: from neural circuits in mice to human therapeutic insights

Chairpersons: **Gian Marco Leggio, Francesco Papaleo**

16.00 Cortico-cortical transfer of socially derived information gates emotion recognition
Anna Maria Borruto

16.20 Reciprocal cortico-amygdala connections regulate prosocial and selfish choices
Diego Scheggia

16.40 Ketamine modulates emotion recognition by reversing age dependent Arc-driven deficits
Sebastiano Alfio Torrisi

17.00 Bridging the scale from genes to systems-level readouts using transcriptomics
Giulio Pergola

ROOM PARIGI

08.30 – 10.30

Convergent modulation of neuroinflammation and immunity through shared molecular pathways in CNS pathologies

Chairpersons: **Majeda Muluhie, Irene Paterniti**

08.30 Targeting the P2X7 receptor in α-synuclein–associated neuroinflammation and immunity: focus on Parkinson and Alzheimer diseases
Alessia Filippone

08.45 What does the ACE2 overexpression reveal? Mapping the neuroimmune landscape in the humanized transgenic CAG-hACE2 mice
Carlotta Siddi

09.00 BACE1 inhibition as a novel pharmacological strategy to counteract neuroinflammation in sepsis-associated encephalopathy
Gustavo Ferreira Alves

09.15 Targeting the EZH2/H3K27me3 axis rescues CDK5/p53 signaling, mitochondrial dysfunction, and neuroinflammation in an *in vitro* model of Alzheimer's disease
Sarah Adriana Scuderi

09.30 CIC-39 as a novel store-operated Ca^{2+} entry negative modulator: a non-immunosuppressive strategy for the treatment of multiple sclerosis
Luigi Azzarone

09.45 Novel PUFA-Lipoic Acid Conjugates as dual-action neuroprotective agents: targeting oxidative stress and neuroinflammation in Alzheimer's disease cell models
Agnese Graziosi

10.00 Pharmacological blockade of IL-1β signaling with anakinra rescues behavioral and synaptic deficits in an α-synuclein model of Parkinson's disease
Federica Servillo

10.15 Leukemia-driven neuroinflammation: linking systemic disease to CNS alterations in AML and CLL
Vjola Tusha

10.30-11.30
Drug combinations as the modern paradigm: opportunities and challenges
Annalisa Capuano, Dario Lidonnici, Patrizia Popoli

11.30-12.30
Artificial Intelligence: the way Forward to a safe healthcare environment
Introduction: **Antonio Addis**
Participants: **Giulio Pompilio, Massimo Riccaboni, Maria Grazia Trotta**

SCIENTIFIC PROGRAMME NON CME

WITH THE UNRESTRICTED GRANT OF GILEAD Creating Possible

14.30 – 16.00
Intestinal inflammation and tissue remodeling: from mechanisms to anti-fibrotic strategies
Chairpersons: **Matteo Fornai, Barbara Romano**

14.30 Diet-driven intestinal fibrosis: lipids and B-cells as key regulators of tissue remodeling
Stefania Vetrano

14.50 Rethinking intestinal fibrosis: the role of the endocannabinoidome system in tissue remodeling
Maria Francesca Nanì

15.10 New anti-fibrotic agents based on biological products
Stefania Bruno

15.30 PPAR agonists in cholestatic liver diseases
Laura Cristoferi

16.00 – 17.30

The senescence–inflammation Axis

Chairpersons: **Fabiana Morroni, Antonio Speciale**

16.00 Neuroinflammation in Huntington's disease: therapeutic potential of senolytic drugs
Andrea Tarozzi

16.15 Targeting the senescence–inflammation axis in acute myeloid leukemia: nutraceutical and pharmacological potential of cucurbitacin D from *Elaeocarpus hainanensis*
Domenico Delfino

16.30 Bioactive agents targeting the senescence-inflammation axis: focus on adipose tissue
Francesco Cimino

16.45 The senescence–inflammation axis in Alzheimer's disease: microglia–oligodendrocyte interactions and therapeutic perspective
Chiara Chemello

17.00 The carnosine journey: unveiling its translational and therapeutic potential as anti-inflammatory and neuroprotective agent in Alzheimer's disease
Giuseppe Caruso

27 November 2026

AUDITORIUM

16.30 – 17.30
Case studies of industrial research and development
Chairperson: **Armando Genazzani**
Speakers: **Luca Bardoscia, Mathias Luz, Klaus Schlueter**

17.30 – 18.00
Beyond words: when emotions become movement
Chairperson: **Annamaria Cattaneo**

18.00 – 20.00
SIF General Assembly
Monica DiLuca, Armando Genazzani

POSTER SESSION

13.00 – 14.30 POSTER SESSION 3

ROOM MADRID

08.30 – 09.30
At the crossroads of eating disorders and addictive behaviors: converging mechanisms towards translational perspective
Chairpersons: **Carlo Cifani, Barbara Fülop, Francesca Mottarlini**

08.30 Eating disorders and addiction: converging neurocognitive and metabolic mechanisms
Laura Di Lodovico

08.45 Deciphering the molecular signature of compulsive exercise as a translational phenotype in anorexia nervosa
Francesca Mottarlini

09.00 Oxytocin receptor distribution in olfactory–limbic circuits relevant for reward and motivational salience in a mouse model of anorexia nervosa
Barbara Eramo

09.15 Antagonism of the dopamine D4 receptor (D4R) blocks compulsive highly palatable food intake in a female rat model of binge eating
Luca Botticelli

09.30 – 11.30

Bispecific antibodies: from the laboratory to the clinic

Chairpersons: **Giorgio Minotti, Giuseppe Toffoli**

09.30 Bispecific (& multispecific) antibodies for cancer therapy: rational development and target selection
Mariangela Figini

09.50 Key features defining the disposition of bispecific antibodies and their efficacy *in vivo*
Antonello Di Paolo

10.10 Bispecific antibodies in hematologic tumors:

10.10 Lymphomas **Umberto Vitolo**

10.30 Myeloma **Michele Cavo**

10.50 Bispecific antibodies in solid tumors
Carmine Pinto

11.10 Bispecific antibodies for cancer therapy: regulatory requirements and health technology assessment
Giuseppe Toffoli

11.30 – 12.30

CAR-T: precision mechanisms and therapeutic innovation

Introduction: **Armando Genazzani**

11.30 CAR-T in onco-hematology: precision mechanisms and therapeutic innovation
Federica Sorà

12.00 CAR-T beyond oncology: opportunities and sustainability
Armando Genazzani

14.30 – 16.00

Dyshomeostasis of non-neuronal cells as a novel and early pharmacological target in neurodegenerative disorders

Chairpersons: **Mariagrazia Grilli, Maria Angela Sortino**

14.30 Microglial protection in early neurodegeneration: impact of external insults
Sara Merlo

14.50 Glia-Neural Stem Cell Interactions in neurodegeneration and stress
Emanuela Pessolano

15.10 Astrocyte-driven oligodendrocyte dysfunction in Alzheimer's disease: molecular pathways of damage and rescue
Caterina Scuderi

15.30 Neuroglia in Amyotrophic Lateral Sclerosis (ALS): translating glial biology into therapeutic strategies
Fabiola De Marchi

15.50 Skeletal muscle as a non-neuronal driver of Amyotrophic Lateral Sclerosis (ALS): from calcium dyshomeostasis to pharmacological intervention
Serenella Anzilotti

ROOM DUBLINO

08.30 – 10.00

Natural compounds and barrier functions: new evidence between gastroprotection, metabolism, and aging

Chairpersons: **Maria Francesca Nanì, Lara Testai**

08.30 New preclinical insights into the gastroprotective role of *Castanea sativa* Mill. and *Cistus x incanus* L. combination
Stefano Piazza

08.45 Multifunctional biological activities of *Angelica sinensis* extract in human skin cell models
Veronica Cocetta

09.00 Citrus pomace-derived phytocomplexes preserve intestinal barrier integrity and modulate gut microbial metabolism under inflammatory conditions
Mariarosaria Ingegneri

09.15 Synergistic anticancer and gastroprotective effects of *Ulva pertusa* in 5-fluorouracil regimens
Alessio Ardizzone

09.30 Bioactivity of *Allium ursinum* leaf extracts: a phytochemical and functional study
Mariachiara Gabriele

09.45 Protocatechuic acid counteracts hypoxia-induced adipocyte senescence and metabolic dysfunction in murine 3T3-L1 Adipocytes
Maria Sofia Molonia

10.00 – 11.30

The next generation of clinical pharmacology and hospital pharmacy: contributions from specialty trainees

Chairpersons: **Paola Crosasso, Alma Martelli, Gianluca Trifirò**

10.00 Development of innovative pharmacogenomic biomarkers for the personalization of therapy with thiopurines in early onset inflammatory bowel disease patients
Giulia Zudeh

10.15 Biosimilar switching in rheumatologic and dermatologic patients: a semi-automatic multidisciplinary approach to ensure appropriateness and sustainability
Alessandra Angarano

10.30 Post-marketing safety of GLP-1 Analogs: a disproportionality analysis of semaglutide and liraglutide in diabetes and weight management using eudravigilance
Victoria Nikitina

10.45 Antibiotic prescribing practices and consumption in a secondary healthcare structure in Bissau: toward context-adapted AMS strategies
Marilisa Giustina Stano

11.00 Pharmacogenetic-guided dosing approach for warfarin therapy: a pharmacoeconomic evaluation of randomized clinical trials
Salvatore Zarrella

11.15 Neurophysiological signatures of alcohol and cocaine craving: preliminary results from the ReBECCA study
Elia Amalfi

11.30 – 12.30 ROUND TABLE

Medicines in the environment: monitoring, treatments and intervention strategies

Chairpersons: **Giovanna Paolone, Raffaella Sorrentino**

Participants: **Ornella Abollino, Nicola Frison, Vitalia Murgia, Maria Teresa Palumbo**

SPONSORED SESSION MERCK

14.30-15.00

Rare tumors: management of unmet medical needs

Chairperson: **Pier Luigi Canonico**

Participants: **Romano Danesi, Armando Genazzani, Giovanni Grignani**

15.30-16.30

Unlocking Transient Receptor Potential (TRP) channels

Chairperson: **Francesco De Logu**

15.30 How TRP channels shape cancer progression: TRPV3 as gatekeeper of invasiveness
Ester Pagano

15.50 An unexpected and druggable TRPA1 signaling in Schwann cells driving chronic pain
Romina Nassini

16.10 Not just brainy, but also brawny: a TR(i)P into latest discoveries
Fabio Arturo Iannotti

ROOM BERLINO

08.30 – 10.00

Drug targeting of cancer cells

Chairpersons: **Stefania Nobili, Federica Papaccio**

08.30 Hypoxia-driven metabolic reprogramming promotes therapy resistance in AML
Lorenzo Manfreda

08.45 TRPV3 loss rewires intestinal epithelial homeostasis toward stemness and a pro-tumorigenic state
Maria Miraglia

09.00 Targeting the Wnt/β-catenin pathway in adrenocortical carcinoma cell lines
Andrea Abate

09.15 Proteomic signatures of acquired doxorubicin resistance in breast cancer: focus on 2D and 3D models and extracellular vesicles
Alessandra Cusimano

09.30 *In vivo* chemical reactions to target and detect tumor hypoxia
Marta Serafini

09.45 Role of miR-223 in NLRP3 inflammasome modulation in oral squamous cell carcinoma orthotopic model
Laura Cucinotta

10.00 – 11.30

Emerging strategies in cardiovascular prevention**

Chairperson: **Vincenzo Calderone**

10.00 Decoupling haemostasis and thrombosis: FXIa inhibition, new frontier in secondary stroke prevention
Andrea Zini

10.30 New therapeutic strategies in the management of hypertension
Cristina Giannattasio

11.00 The quest to cover unmet needs in uncontrolled hypertensive patients
Gianfranco Parati

11.30-12.30 SIF-EGUALIA Symposium

From generic and biosimilar medicines to essential medicines: new scientific and industrial challenges to ensure access to healthcare in Europe

11.30 Introduction
Annalisa Capuano

11.35 New European challenges for generic, biosimilar and essential medicines: from research to industrial resilience
Adrian van den Hoven

11.55 The Italian off-patent medicines ecosystem: scientific innovation, manufacturing, and access to healthcare
Michele Uda

12.15 Final discussion with the audience on the main emerging scientific issues and future challenges related to access to medicines, pharmaceutical research, and industrial sustainability

14.30 – 16.00 SIF-FARMINDUSTRIA Symposium

Clinical pharmacology and the competitiveness of the Italian system: between global pressures and national regulatory choices

Chairperson: **Paolo Siviero**

14.30 The global pharmaceutical context: new pressures on national systems
Fulvio Berardo

14.45 Pre- and post-commercialization evidence generation: leveraging an unexploited synergy for regulatory decisions
Gianluca Trifirò

15.00 Clinical trials and Italy's competitiveness: strengthening the upstream position through process review and incentive mechanisms
Mariangela Amoroso

15.15 Revising the therapeutic armamentarium: can pre- and post-marketing evidence synergy offer a viable alternative?
Andrea Marcellusi

15.30 Round table — pre- and post-marketing evidence synergy as a driver of regulatory and clinical decision-making: a shared strategy between academia and industry
Mario Mangrella, Patrizia Popoli, Anna Maria Porrini, Giuseppe Toffoli

16.00 – 16.30
Assembly of the SIF Clinical Pharmacology Section
Annalisa Capuano

ROOM LONDRA

08.30 – 10.00
Novel and 3R-compliant platforms for early translational research in rare diseases
Chairpersons: **Elisabetta Bigagli, Ramona Meanti**

08.30 Apoptosis and motor deficits in SPG76 hereditary spastic paraplegia: Calpain 2 inhibition as therapeutic strategy
Giulia Guarato

08.45 Brain organoids to identify therapeutic targets for neurodevelopmental disorders induced by thyroid deficiency as for the rare Allan-Herndon-Dudley Syndrome (AHDS)
Francesca Ciarpella

09.00 Development of a functional human neuronal model for the study of ataxia-telangiectasia
Giulia Lecchi

09.15 Integrative modelling of degenerative and metabolic disorders in *Drosophila melanogaster*: pathogenic mechanisms and experimental therapeutic approaches
Simona Del Quondam

09.30 ATM-knockout human neural progenitors as a sophisticated cellular platform for investigating ataxia-telangiectasia pathophysiology and for drug repurposing strategy
Giulia Boni

09.45 Towards a 3R-compliant integrated approach: innovative preclinical platforms for rare neuromuscular diseases and channelopathies
Lisamaura Tulimiero

10.00 – 11.30 ROUND TABLE
Transitional care in rare diseases: regulatory and therapeutic pathways for orphan drugs and advanced therapies
Chairpersons: **Annamaria De Luca, Armando Genazzani**
Participants: **Maria Adelaide Bottaro, Pier Luigi Canonico, Luisa De Sanctis, Graziana Diez Roux, Andrea Marcellusi, Patrizia Popoli, Annalisa Scopinaro, Giovanna Scroccaro**

11.30-12.00
Givinostat in Duchenne muscular dystrophy: an Italian story of scientific innovation, translational research and patient partnership **
Paolo Bettica

SPONSORED SESSION

12.00-12.30

Beyond individual syndromes: how should the regulatory approach to DEEs evolve

Emilo Russo

14.30 – 15.30 ROUND TABLE

Safety and regulatory framework for medicinal plants and nutraceuticals

Chairpersons: **Francesca Borrelli, Antonella Di Sotto, Annabella Vitalone**

Participants: **Alessandro Assisi, Marco Biagi, Gioacchino Calapai, Silvia Di Giacomo**

15.30 – 16.30

Assembly of the SIF Early Career Pharmacologists Group

Maria Antonietta Riemma

ROOM ISTANBUL

08.30 – 09.30

The metastatic partnership: vascular, stromal and immune interaction in the journey of circulating tumor cells

Chairpersons: **Michela Campolo, Valerio Ciccone**

08.30 The ascitic compartment in ovarian cancer: circulating tumor cells and tumor–microenvironment crosstalk
Francesca Gorini

08.45 Hydrogen sulfide–driven reprogramming of the glioblastoma microenvironment: cancer-associated fibroblast (CAF) activation, sphingosine-1-phosphate (S1P) axis and stemness
Giovanna Casili

09.00 Circulating tumor cell cluster dynamics in triple-negative breast cancer
Federica Carolina Balestrero

09.15 Beyond angiogenesis: pro-inflammatory activated pericytes in breast cancer progression
Marianna Moro

9.30 – 11.00

Pharmacogenetics in personalized medicine

Chairpersons: **Rossana Roncato, Alessio Squassina**

9.30 Targeting metabolism in oncology
Armando Genazzani

9.50 Pharmacogenetics in the Italian National Health System: a roadmap to clinical implementation
Erika Cecchin

10.10 Pharmacogenetics and therapeutic drug monitoring: integrating tools for personalized therapy
Jessica Cusato

10.30 Implementing clinical pharmacogenomics in Europe: challenges and future perspectives
Jesse Swen

11.00 – 12.30

The role of pharmacology in clinical precision oncology

Chairpersons: **Antonio D'Avolio, Enrico Mini**

11.00 Bioinformatic (AI) models-based approaches in the development and clinical application of anticancer drugs
Stefano Fogli

11.20 Therapeutic drug monitoring as a tool to enhance efficacy and reduce toxicity in cancer therapy
Lucia Lisi

11.40 Clinical relevance of drug - drug interactions in cancer patients
Emanuel Raschi

12.00 New phenotypes of cardiotoxicity induced by cancer therapies
Giorgio Minotti

14.30 – 16.00

Teaching 2.0: innovative methodological approaches

Chairpersons: **Carla Ghelardini, Anna Maria Pittaluga**

14.30 Innovating university courses through a blended learning model—integrating Massive Open Online Courses (MOOCs) and Open Educational Resources (OER)
Maria Renza Guelfi

14.45 Team-Based Learning (TBL) and pharmacology: a possible combination?
Antonella Lotti

15.00 Pharmacy Services: Educational and practical simulation of professional activities
Marco Milanese

15.15 Assembly of the SIF CNFU Section
Carla Ghelardini

ROOM PARIGI

08.30 – 10.00

Deconstructing neurodevelopmental disorders: from neurobiological mechanisms to clinical trials

Chairpersons: **Maria Italia, Michele Santoni**

08.30 Altered post-trauma neural activity in the basolateral amygdala is associated with susceptibility to PTSD
Giulia Chiacchierini

08.45 IAMA-6 successfully completed phase-1 trial, progressing clinical development in neurodevelopmental disorders
Annalisa Savardi

09.00 Convergent Negr1 upregulation drives core behaviors and identifies an autism biomarker
Mariam Marie Chellali

09.15 Cardiac interoception and insular cortex: a pathway to understanding social deficits in autism
Alessandra Panzeri

09.30 Unraveling the differential impact of prenatal THC and CBD exposure on neurodevelopmental trajectories: long-term molecular and behavioral outcomes
Serena Di Martino

09.45 Prenatal microglial depletion alters neurodevelopmental trajectories following Early Immune Activation in mice
Naomi Ciano Albanese

11.00 – 12.30

Marine Pharmacology: a sea of opportunities

Chairpersons: **Mario Dell'Agli, Giustino Orlando, Lara Testai**

11.00 Pharmacological research inside blue economy: from results to perspectives
Paola Nieri

11.20 Evaluation of the anti-inflammatory and anti-hyperalgesic properties of *Posidonia oceanica* (L.) Delile in preclinical pain models
Laura Micheli

11.40 Marine bioactive against cancer from *Zostera marina*
Paola De Cicco

12.00 From marine natural products to cancer therapy
Lorenzo D'Ambrosio

12.30 – 13.30

Molecular Tumor Board Network

Chairpersons: **Cristiano Chiamulera, Paola Fadda**

Introduction: **Romano Danesi**

Round table and discussion

Erika Cecchin, Giammarco Baiardi, Domenico Vittorio Delfino

13.30-14.30

Phase I Clinical Trial Network

Romano Danesi, Giovanni Gori, Sandra Sigala, Maurizio Taglialatela

14.30 – 16.00

Sex-aware pharmacological research: from scientific evidence to experimental practice

Chairpersons: **Flavia Franconi, Luigia Trabace**

14.30 Rethinking sex in pharmacology: from bias to sex contextualism
Ilaria Campesi

14.50 From concept to practice: implementing sex-aware pharmacology in experimental research
Maria Grazia Cattaneo

15.10 From data to evidence: statistical strategies to detect sex differences in pharmacological research
Giovanni Sotgiu

15.30 Are the 3Rs and the need for gender balance in animal studies conflicting?
Giuliano Grignaschi

16.00 – 16.30

Assembly of the SIF Education Section

Giuseppe Cirino

28 November 2026

AUDITORIUM

11.30 – 12.30
EPHAR Lecture: Lysosomal calcium signalling: from discovery to the clinic
Introduced by **Armando Genazzani, Maria J. Sanz**
Speaker: **Antony Galione**

12.30 – 13.00
Conclusions and awards
Monica DiLuca, Armando Genazzani

ROOM MADRID

08.30-10.00
Advances in alternative research methods
Chairpersons: **Elisabetta Caiazzo, Elena Lucarini**

08.30 A novel UHPLC-MS/MS method for the plasmatic quantification of cabotegravir from MITRA - Volumetric Absorptive Microsampling (VAMS) devices
Sara Soloperto

08.45 Modeling chemotherapy-induced peripheral neuropathy in human dorsal root ganglia organoids
Maria Giovanna Cataldi

09.00 hiPSC-Derived DRG organoids model differential vulnerability to sorbitol-induced neurotoxicity and neuroprotection by MAP4K inhibitors in diabetic neuropathy
Daniel Venturi

09.15 Modelling hypertension-associated neuroinflammation using a human millifluidic system
Benedetta Mercuriali

09.30 Development of 3D models of leiomyosarcoma for the evaluation of doxorubicin–peposertib combination therapy
Antonella Simone

09.45 Methylphenidate modulates alpha-synuclein/Synapsin III co-pathology in iPSC-derived striatal organoids from multiple system atrophy patients
Gaia Faustini

10.00-11.00
Managing uncertainty and non-traditional outcomes in drug approval and reimbursement
Armando Genazzani, Pier Paolo Olimpieri, Francesco Perrone, Entela Xoxi

SCIENTIFIC PROGRAMME NON CME

ROOM DUBLINO

08.30 – 09.30

Frailty in complex comorbidities

Chairpersons: **Arianna Pani, Maria Antonietta Riemma**

08.30 Frailty in accelerated aging: sex- and time-dependent responses to a multi-drug treatment in SAMP8 mice
Martina Monaco

08.45 Delphi expert consensus to develop recommendations for medication adherence interventions in older adults with multimorbidity and polypharmacy
Stefano Scotti

09.00 Pharmacological and clinical impact of medication review on older people in general practice: a systematic review and meta-analysis of experimental studies
Irene Cristini

09.15 Polypharmacy in chronic heart failure: the impact of medication review and the role of the multidisciplinary team
Miriam Traficante

09.30 – 10.30

Intestinal microbiota in extra-digestive disorders

Chairpersons: **Clelia Di Salvo, Carla Petrella**

09.30 Bridging gut dysbiosis and pain: modulatory effect of N-palmitoyl D-glucosamine
Federica Ricciardi

09.45 Microbiota-mediated crosstalk between the gut and the vascular system: functional insights for cardiovascular protection of probiotic-derived formulations
Lorenzo Flori

10.00 Long lasting sex-dependent influence of antibiotic-induced dysbiosis and *Lacticaseibacillus rhamnosus* GG (ATCC 53103) on gastrointestinal motility and behavior
Annalisa Bosi

10.15 OEA-producing Lactobacillus paracasei F19 improves metabolic and behavioral disorders by restoring intestinal permeability and microbiota-gut-brain axis in high-fat diet-induced obese mice
Irene Palenca

ROOM BERLINO

08.30 – 10.00

Joint SIF–SIICA Symposium: targeting immunometabolism – Young investigators rewiring immune function

Chairpersons: **Marco Gargaro, Giorgia Manni**

08.30 Non-enzymatic function of IDO1 as immunometabolic driver in the tumor microenvironment: therapeutic implications
Sofia Rossini

08.45 Targeting IDO1 to rewire cDC1 metabolism and restore anti-tumor immunity
Giada Mondanelli

09.00 CD71-dependent iron metabolism in RORγt^{+} Tregs shapes intestinal homeostasis and tumor immunity
Alessandra Pinzon Grimaldos

09.15 Effects of genetic lysosomal acid lipase deficiency on immune cell function: focus on dendritic cells
Carola Garavaglia

09.30 Caloric restriction as a metabolic-immunological strategy to improve clinical and cellular outcomes in relapsing-remitting multiple sclerosis
Alessandra Colamatteo

09.45 A siRNA-based approach to target Oncostatin M in bone marrow macrophages as an anti-inflammatory and pro-regenerative therapy for diabetic vascular disease
Carlotta Boscaro

10.00 – 11.30

Inflammation and response to pharmacological treatment in psychiatric disorders

Chairpersons: **Annamaria Cattaneo, Edoardo Spina**

10.00 Targeting Inflammation to improve symptoms in non-responder patients: the importance of immune stratification
Annamaria Cattaneo

10.20 Machine learning for capturing inflammation-related heterogeneity in mood disorders
Benedetta Vai

10.40 Impact of inflammation on antidepressant pharmacokinetics: navigating literature evidence, areas of uncertainty, and perspectives from plasma concentration data
Giuseppe Cicala

11.00 Molecular bridges among lifestyles, depressive symptoms and cardiometabolic traits
Alessandro Gialluisi

ROOM LONDRA

08.30 – 10.00

Targeting cellular and structural components of the tumor microenvironment

Chairpersons: **Raffaella Belvedere, Monica Notarbartolo di Villarosa**

08.30 From tumor to microenvironment: impact of 5-azacytidine adjuvant drug targeting Annexin A1 on oral squamous cell carcinoma progression
Nunzia Novizio

08.45 Decoding hypoxia-adapted regulatory T cells in cholangiocarcinoma through spatial proteomics
Luigi Cari

09.00 Overcoming therapy resistance in a rare cancer: targeting the tumor microenvironment in adrenocortical carcinoma
Mariangela Tamburello

09.15 Antitumor activity of *Moringa oleifera* extract in multiple myeloma cell and in bone marrow microenvironment model
Ilaria Saltarella

09.30 Targeting ERO1α triggers tumor immunosurveillance in triple-negative breast cancer
Alessandro Cherubini

09.45 Loss of AIM2 limits tumor growth in a mouse model of lung adenocarcinoma resistant to immunotherapy
Chiara Colarusso

10.00 – 11.30 ROUND TABLE

Clinical pharmacology and the National Health System

Chairpersons: **Erika Cecchin, Concita Rafaniello**

Participants: **Valeria Conti, Salvatore Crisafulli, Marzia Del Re, Antonello Di Paolo, Liberata Sportiello, Gabriele Stocco**

ROOM ISTANBUL

08.30 – 09.30

Real-world evidence of biologic drugs in immune mediated inflammatory diseases

Chairpersons: **Irma Convertino, Andrea Spini**

08.30 Real-world effectiveness, treatment persistence, and safety of biologic therapies in inflammatory bowel diseases: a prospective pharmacovigilance study
Maria Antonietta Barbieri

08.45 Biologics in psoriasis and psoriatic arthritis: a one-year real-world study from Calabria
Lorenza Guarnieri

09.00 Evaluating the representativeness of pivotal trials for biologics in pediatric immune-mediated inflammatory diseases: a population-based study using the Italian VALORE distributed database network
Chiara Bellitto

09.15 Output from the Veneto Region Working Group on high-cost drugs for immune-mediated inflammatory diseases: harmonizing prescribing appropriateness and cost-containment regional governance
Giacomo Vitturi

09.30 – 10.30

Stress across the lifespan: mechanistic insights

Chairpersons: **Natasha Irrera, Giulia Federica Mancini, Luísa Teixeira Santos**

09.30 Targeting hypothalamic histaminergic neurons to modulate stress resilience: pharmacological and chemogenetic approaches
Alessia Costa

09.45 Early-life stress: from later psychopathologies to pharmacological interventions
Giulia Federica Mancini

10.00 Abnormal trajectory of dopaminergic neurodevelopment and stress-related behaviors following perinatal paracetamol exposure
Valeria Serra

10.15 Early life stress and long term negative behavioral outcomes dissecting the role of the gut microbiome in clinical and preclinical studies
Floriana De Cillis

10.30-11.30

In-training clinical pharmacologists/toxicologists and hospital pharmacists: the SIF Contest

Paolo Abrate, Alma Martelli, Nicoletta Luxi, Gianluca Trifirò

ROOM PARIGI

08.30 – 10.00

Substance use disorders in adolescence and adulthood: neurobiological adaptations, behavioral outcomes, and their clinical relevance

Chairpersons: **Nicholas Pintori, Laura Rullo**

08.30 A procedure to identify persistent and effort-independent individual differences in preference for heroin over rewarding social interaction
Soami Filippo Zenoni

08.45 Stress-related neuroadaptations following adolescent exposure to the synthetic cannabinoid 5F-MDMB-PICA
Francesca Caria

09.00 Cebranopadol: a novel dual NOP/MOP receptor agonist to treat fentanyl use disorder and fentanyl induced respiratory depression in a rat model of addiction
Manthoula Olga Kyratzi

09.15 Prolonged nicotine exposure, via electronic cigarettes, selectively enhances the transcription of Bdnf/TrkB and elevates dynorphin peptide and OLIG2 levels in the rat VTA
Camilla Morosini

09.30 Prenatal THC exposure alters kynurenine pathway and stress responsivity in the ventral tegmental area
Edoardo Tiziani

09.45 Investigating the ability of LSD to revert fentanyl-induced maladaptive neuroplastic changes
Fabio Ruto

10.00 – 11.30

Post-transcriptional regulation: the molecular interface between health and disease

Chairpersons: **Nicoletta Galeotti, Alessia Pascale**

10.00 Translational control as a therapeutic target
Denise Sighel

10.20 MicroRNAs and ocular diseases
Chiara Bianca Maria Platania

10.40 Modulation via drug therapy of HuR in multiple sclerosis
Nicoletta Marchesi

11.00 A possible role for the RNA-binding protein HuD in Amyotrophic Lateral Sclerosis
Alessandro Rosa

11.15 Post-transcriptional mechanisms in cellular aging
Sofia Quadrino

*** These sessions are restricted to physicians and pharmacists only*

FACULTY

Andrea Abate	*Brescia*
Ornella Abollino	*Torino*
Paolo Abrate	*Torino*
Antonio Addis	*Roma*
Federica Agosta	*Milano*
Anna Ardissone	*Milano*
Elia Amalfi	*Firenze*
Ilaria Ammendolia	*Messina*
Mariangela Amoroso	*Milano*
Antonietta Anatriello	*Napoli*
Jacopo Angelini	*Udine*
Andrea Antinori	*Roma*
Luca Antonioli	*Pisa*
Serenella Anzilotti	*Roma*
Alessio Ardizzone	*Roma*
Alessandro Assisi	*Roma*
Luigi Azzarone	*Roma*
Claudia Bagni	*Roma*
Giammarco Baiardi	*Genova*
Matilde Balbi	*Genova*
Simone Baldovino	*Torino*
Federica Balestrero	*Novara*
Andrea Baragetti	*Milano*
Maria Antonietta Barbieri	*Messina*
Luca Bardoscia	*Milano*
Sebastiano Bariselli	*Milano*
Vera Battini	*Milano*
Carmela Belardo	*Roma*
Chiara Bellitto	*Verona*
Raffaella Belvedere	*Salerno*
Cristina Benatti	*Modena*
Alberto Benussi	*Trieste*
Fulvio Berardo	*Roma*
Fabrizio Bert	*Torino*
Valentina Bertaglia	*Torino*
Chiara Bertasini	*Verona*
Ilaria Bertocchi	*Torino*
Paolo Bettica	*Milano*
Marco Biagi	*Parma*
Alessia Bichicchi	*Siena*
Elisabetta Bigagli	*Firenze*
Brigida Boccanegra	*Bari*
Angela Boccia	*Bologna*
Marina Boido	*Torino*
Giulia Boni	*Novara*
Martina Bonifazi	*Ancona*
Vittoria Borgonetti	*Siena*
Francesca Borrelli	*Napoli*
Anna Maria Borruto	*Camerino*
Carlotta Boscaro	*Padova*
Annalisa Bosi	*Varese*
Maria Adelaide Bottaro	*Roma*
Luca Botticelli	*Camerino*
Marco Bozzali	*Torino*
Sara Boumya	*Torino*
Riccardo Brambilla	*Pavia*
Vincenzo Brancaleone	*Cagliari*
Federico Brandalise	*Cagliari*
Marialuisa Brandi	*Firenze*
Stefania Bruno	*Torino*
Andrea Burgalassi	*Firenze*
Alessia Cafaro	*Genova*
Lucia Caffino	*Milano*
Cecilia Cagnotta	*Napoli*
Elisabetta Caiazzo	*Napoli*
Gioacchino Calapai	*Messina*
Vincenzo Calderone	*Pisa*
Alessia Campagna	*Roma*
Ilaria Campesi	*Sassari*
Paola Campo	*Milano*
Michela Campolo	*Messina*
Pier Luigi Canonico	*Novara*
Daniele Caprioli	*Roma*
Annalisa Capuano	*Napoli*
Irene Capuano	*Seattle*
Filippo Caraci	*Perugia*
Luigi Cari	*Perugia*
Francesca Caria	*Cagliari*
Giuseppe Caruso	*Catania*
Giovanna Casili	*Messina*
Paola Cassoni	*Torino*
Maria Giovanna Cataldi	*Firenze*
Dario Cattaneo	*Milano*
Annamaria Cattaneo	*Milano*
Maria Grazia Cattaneo	*Milano*
Michele Cavo	*Bologna*
Eleonora Cecchin	*Aviano*
Erika Cecchin	*Aviano*
Camilla Celentano	*Napoli*
Alessandro Giovanni Cerchiara	*Bari*
Ida Cerqua	*Napoli*
Stefania Ceruti	*Roma*
Mariam Marie Chellali	*Genova*
Chiara Chemello	*Padova*
Alessandro Cherubini	*Milano*
Giulia Chiacchierini	*Roma*
Cristiano Chiamulera	*Verona*
Clara Ciampi	*Firenze*
Naomi Ciano Albanese	*Roma*
Claudia Ciarla	*Roma*
Francesca Ciarpella	*Verona*
Giuseppe Cicala	*Messina*
Roberto Ciccocioppo	*Siena*
Valerio Ciccone	*Siena*

FACULTY

♦ **Federico Ciceri**	*Pavia*
♦ **Carlo Cifani**	*Camerino*
♦ **Francesco Cimino**	*Messina*
♦ **Giuseppe Cirino**	*Napoli*
♦ **Mario Salvatore Clerici**	*Milano*
♦ **Marinella Clerico**	*Torino*
♦ **Veronica Cocetta**	*Padova*
♦ **Alessandra Colamatteo**	*Napoli*
♦ **Chiara Colarusso**	*Salerno*
♦ **Enrico Collantoni**	*Padova*
♦ **Massimo Collino**	*Torino*
♦ **Fabrizio Condorelli**	*Novara*
♦ **Elena Conte**	*Bari*
♦ **Federica Conti**	*Catania*
♦ **Valeria Conti**	*Salerno*
♦ **Irma Convertino**	*Pisa*
♦ **Alberto Corsini**	*Milano*
♦ **Alessia Costa**	*Firenze*
♦ **Enrico Costa**	*Roma*
♦ **Giada Crescioli**	*Firenze*
♦ **Salvatore Crisafulli**	*Verona*
♦ **Irene Cristini**	*Verona*
♦ **Laura Cristoferi**	*Milano*
♦ **Paola Crosasso**	*Torino*
♦ **Laura Cucinotta**	*Messina*
♦ **Debora Curci**	*Trieste*
♦ **Jessica Cusato**	*Torino*
♦ **Alessandra Cusimano**	*Palermo*
♦ **Lorenzo Da Dalt**	*Milano*
♦ **Claudio D'Addario**	*Teramo*
♦ **Paolo Dalla Zuanna**	*Trieste*
♦ **Lorenzo D'Ambrosio**	*Torino*
♦ **Romano Danesi**	*Milano*
♦ **Ilari D'Aprile**	*Milano*
♦ **Francesca Dattrino**	*Pavia*
♦ **Danilo D'Avino**	*Napoli*
♦ **Antonio D'Avolio**	*Torino*
♦ **Antonella De Angelis**	*Napoli*
♦ **Emanuela De Bellis**	*Napoli*
♦ **Carmen De Caro**	*Catanzaro*
♦ **Paola De Cicco**	*Napoli*
♦ **Floriana De Cillis**	*Milano*
♦ **Francesco De Logu**	*Firenze*
♦ **Annamaria De Luca**	*Bari*
♦ **Fabiola De Marchi**	*Novara*
♦ **Luisa De Sanctis**	*Torino*
♦ **Lucia Del Mastro**	*Genova*
♦ **Simona Del Quondam**	*Viterbo*
♦ **Marzia Del Re**	*Roma*
♦ **Domenico Delfino**	*Perugia*
♦ **Oscar Della Pasqua**	*Londra*
♦ **Mario Dell'Agli**	*Milano*
♦ **Giulia Dematteis**	*Bordeaux*
♦ **Silvia Di Giacomo**	*Roma*
♦ **Roberto Di Lauro**	*Napoli*
♦ **Laura Di Lodovico**	*Parigi*
♦ **Massimo Di Maio**	*Torino*
♦ **Serena Di Martino**	*Catania*
♦ **Noemi Di Muraglia**	*Camerino*
♦ **Raffaella Di Napoli**	*Napoli*
♦ **Antonello Di Paolo**	*Pisa*
♦ **Giovanni Di Perri**	*Torino*
♦ **Clelia Di Salvo**	*Pisa*
♦ **Antonella Di Sotto**	*Roma*
♦ **Graziana Diez Roux**	*Pozzuoli*
♦ **Monica Diluca**	*Milano*
♦ **Giorgia Dinoi**	*Bari*
♦ **Enrico Domenici**	*Trento*
♦ **Esi Domi**	*Camerino*
♦ **Valentina Drago**	*Novara*
♦ **Giacomo Einaudi**	*Camerino*
♦ **Barbara Eramo**	*Stockholm*
♦ **Giuseppe Ercolano**	*Napoli*
♦ **Emanuela Esposito**	*Messina*
♦ **Erika Esposito**	*Napoli*
♦ **Roberta Facchinetti**	*Roma*
♦ **Paola Fadda**	*Cagliari*
♦ **Sofia Faggin**	*Tolouse*
♦ **Francesca Fallarino**	*Perugia*
♦ **Gaia Faustini**	*Brescia*
♦ **Gustavo Ferreira Alves**	*Torino*
♦ **Mariangela Figini**	*Milano*
♦ **Amelia Filippelli**	*Salerno*
♦ **Arianna Filippelli**	*Roma*
♦ **Alessia Filippone**	*Roma*
♦ **Lorenzo Flori**	*Pisa*
♦ **Stefano Fogli**	*Pisa*
♦ **Luigi Formisano**	*Napoli*
♦ **Matteo Fornai**	*Pisa*
♦ **Silvia Franchi**	*Milano*
♦ **Flavia Franconi**	*Sassari*
♦ **Martina Franzin**	*Trieste*
♦ **Nicola Frison**	*Verona*
♦ **Marzia Friuli**	*Milano*
♦ **Barbara Fülop**	*Pecs*
♦ **Fabio Fumagalli**	*Milano*
♦ **Mariachiara Gabriele**	*Pescara*
♦ **Silvana Gaetani**	*Roma*
♦ **Luca Gallelli**	*Catanzaro*
♦ **Carlotta Galeone**	*Milano*
♦ **Nicoletta Galeotti**	*Firenze*
♦ **Antony Galione**	*Oxford*
♦ **Martina Gambron**	*Aviano*
♦ **Carola Garavaglia**	*Milano*
♦ **Silvia Garazzino**	*Torino*
♦ **Marco Gargaro**	*Perugia*
♦ **Caterina Garone**	*Bologna*
♦ **Milo Gatti**	*Bologna*
♦ **Gianluca Gazzaniga**	*Roma*
♦ **Armando Genazzani**	*Torino*
♦ **Carla Ghelardini**	*Firenze*
♦ **Alessandro Gialluisi**	*Bari*

FACULTY

♦ Cristina Giannattasio	Milano
♦ Riccardo Giossi	Milano
♦ Bianca Goffredo	Roma
♦ Giovanni Gori	Pisa
♦ Francesca Gorini	Bologna
♦ Agnese Graziosi	Bologna
♦ Giuliano Grignaschi	Milano
♦ Marigrazia Grilli	Novara
♦ Ambra Grolla	Novara
♦ Giulia Guarato	Bosisio Parini
♦ Lorenza Guarnieri	Catanzaro
♦ Maria Renza Guelfi	Firenze
♦ Gaetano Guglielmi	Roma
♦ Giorgia Serena Gullotta	Troina
♦ Annamaria Iagnocco	Torino
♦ Luigi Francesco Iannone	Reggio Emilia
♦ Fabio Arturo Iannotti	Napoli
♦ Stefania Iervolino	Napoli
♦ Paola Imbrici	Bari
♦ Mariarosaria Ingegneri	Messina
♦ Natasha Irrera	Messina
♦ Maria Italia	Milano
♦ Manthoula Olga Kyratzi	Camerino
♦ Paola Laghetti	Bari
♦ Adriano Lama	Pavia
♦ Cristina Lanni	Pavia
♦ Giulia Lecchi	Novara
♦ Gian Marco Leggio	Catania
♦ Ludovica Lela	Potenza
♦ Antonella Liantonio	Bari
♦ Dario Lidonnici	Milano
♦ Lucia Lisi	Roma
♦ Alessandra Lodi	Torino
♦ Giorgia Loreto	Catania
♦ Antonella Lotti	Foggia
♦ Marianna Lucafo	Trieste
♦ Elena Lucarini	Firenze
♦ Gaia Lusoli	Bologna
♦ Thomas Lutz	Zurich
♦ Nicoletta Luxi	Verona
♦ Mathias Luz	Mannheim
♦ Pasquale Maffia	Napoli
♦ Francesco Maione	Napoli
♦ Nunzia Maisto	Roma
♦ Alessandra Manca	Torino
♦ Giulia Federica Mancini	Roma
♦ Lorenzo Manfreda	Milano
♦ Giorgia Manni	Perugia
♦ Elena Mantovani	Novara
♦ Elena Marcello	Milano
♦ Andrea Marcellusi	Milano
♦ Nicoletta Marchesi	Pavia
♦ Alessia Marchesin	Milano
♦ Francesco Margiotta	Salerno
♦ Marialuisa Sveva Marozzi	Bari
♦ Alma Martelli	Pisa
♦ Nello Martini	Roma
♦ Stefania Marzocco	Salerno
♦ Ishii Masaru	Osaka
♦ Mirco Masi	Genova
♦ Andrea Maurizio	Bologna
♦ Ramona Meanti	Milano
♦ Francine Medjiofack Djeujo	Padova
♦ Stefania Melini	Napoli
♦ Miriam Melis	Cagliari
♦ Anna Meloni	Cagliari
♦ Benedetta Mercuriali	Milano
♦ Sara Merlo	Catania
♦ Francesco Miceli	Napoli
♦ Laura Micheli	Firenze
♦ Maria Vittoria Micioni Di Bonaventura	Camerino
♦ Gianluca Miglio	Torino
♦ Noemi Milan	Aviano
♦ Marco Milanese	Genova
♦ Cinzia Milito	Roma
♦ Enrico Mini	Firenze
♦ Giorgio Minotti	Roma
♦ Maria Miraglia	Napoli
♦ Davida Mirra	Napoli
♦ Maria Sofia Molonia	Messina
♦ Martina Monaco	Genova
♦ Matteo Monami	Firenze
♦ Giada Mondanelli	Perugia
♦ Andrea Maria Morace	Napoli
♦ Ilaria Maria Morella	Pavia
♦ Marianna Moro	Novara
♦ Camilla Morosini	Bologna
♦ Fabiana Morroni	Bologna
♦ Francesca Mottarlini	Milano
♦ Majeda Muluhie	Milano
♦ Antonio Munafo	Firenze
♦ Vitalia Murgia	Cagliari
♦ Laura Musazzi	Milano
♦ Maria Francesca Nanì	Napoli
♦ Sofia Nasini	Padova
♦ Romina Nassini	Pisa
♦ Nicol Pia Navatti	Napoli
♦ Paola Nieri	Pisa
♦ Victoria Nikitina	Bologna
♦ Robert Nisticò	Roma
♦ Stefania Nobili	Firenze
♦ Giuseppe Danilo Norata	Milano
♦ Monica Notarbartolo di Villarosa	Palermo
♦ Nunzia Novizio	Campobasso
♦ Pier Paolo Olimpieri	Rome
♦ Chiara Oliviero	Pavia
♦ Elena Olmastroni	Milano
♦ Ciriana Orabona	Perugia
♦ Giustino Orlando	Pescara
♦ Elena Osto	Graz
♦ Simona Pace	Roma
♦ Ester Pagano	Napoli

FACULTY

♦ **Barbara Pagliarani**	*Bologna*
♦ **Irene Palenca**	*Roma*
♦ **Alice Palermiti**	*Torino*
♦ **Marcella Palumbo**	*Parma*
♦ **Maria Teresa Palumbo**	*Brugherio*
♦ **Arianna Pani**	*Milano*
♦ **Alessandra Panzeri**	*Genova*
♦ **Giovanna Paolone**	*Verona*
♦ **Federica Papaccio**	*Salerno*
♦ **Francesco Papaleo**	*Genova*
♦ **Gianfranco Parati**	*Milano*
♦ **Alessia Angela Pascale**	*Pavia*
♦ **Lucia Carmela Passacatini**	*Roma*
♦ **Francesca Patarnello**	*Milano*
♦ **Vincenzo Patella**	*Salerno*
♦ **Irene Paterniti**	*Messina*
♦ **Federico Pea**	*Bologna*
♦ **Giulio Pergola**	*Bari*
♦ **Michela Perrone**	*Napoli*
♦ **Francesco Perrone**	*Napoli*
♦ **Pasquale Perrone Filardi**	*Napoli*
♦ **Emanuela Pessolano**	*Novara*
♦ **Sandra Petraglia**	*Roma*
♦ **Francesco Petragnano**	*L'Aquila*
♦ **Carla Petrella**	*Napoli*
♦ **Stefano Piazza**	*Milano*
♦ **Silvia Piccirillo**	*Ancona*
♦ **Benedetta Pieroni**	*Perugia*
♦ **Carmine Pinto**	*Reggio Emilia*
♦ **Nicholas Pintori**	*Cagliari*
♦ **Alessandra Pinzon Grimaldos**	*Roma*
♦ **Eugenia Piragine**	*Pisa*
♦ **Claudio Pirozzi**	*Napoli*
♦ **Anna Maria Pittaluga**	*Genova*
♦ **Chiara Bianca Maria Platania**	*Catania*
♦ **Elisabetta Poluzzi**	*Bologna*
♦ **Giulio Pompilio**	*Milano*
♦ **Patrizia Popoli**	*Roma*
♦ **Sofia Quadrino**	*Firenze*
♦ **Concetta Rafaniello**	*Napoli*
♦ **Claudia Raineri**	*Torino*
♦ **Emanuel Raschi**	*Bologna*
♦ **Gloria Ravegnini**	*Bologna*
♦ **Benedetta Riboldi**	*Milano*
♦ **Massimo Riccaboni**	*Lucca*
♦ **Carlo Riccardi**	*Perugia*
♦ **Consiglia Riccardi**	*Napoli*
♦ **Federico Riccardi**	*Trieste*
♦ **Federica Ricciardi**	*Napoli*
♦ **Juliet Richetto**	*Zurigo*
♦ **Maria Antonietta Riemma**	*Napoli*
♦ **Marco Andrea Riva**	*Milano*
♦ **Beatrice Riva**	*Novara*
♦ **Veronica Rivi**	*Modena*
♦ **Laura Rizzi**	*Milano*
♦ **Adele Romano**	*Roma*
♦ **Barbara Romano**	*Napoli*
♦ **Benedetta Romano**	*Napoli*
♦ **Rossana Roncato**	*Udine*
♦ **Alessandro Rosa**	*Roma*
♦ **Antonietta Rossi**	*Napoli*
♦ **Francesco Rossi**	*Napoli*
♦ **Silvia Rossi**	*Pavia*
♦ **Sofia Rossini**	*Perugia*
♦ **Michelangelo Rottura**	*Messina*
♦ **Fiorentina Roviezzo**	*Napoli*
♦ **Barbara Ruaro**	*Trieste*
♦ **Laura Rullo**	*Bologna*
♦ **Francesco Russiani**	*Udine*
♦ **Giulia Russo**	*Messina*
♦ **Emilio Russo**	*Catanzaro*
♦ **Fabio Ruto**	*Milano*
♦ **Paola Giuseppina Sacerdote**	*Milano*
♦ **Ilaria Saltarella**	*Bari*
♦ **Michele Santoni**	*Cagliari*
♦ **Maria J. Sanz**	*Valencia*
♦ **Annalisa Savardi**	*Milano*
♦ **Anella Saviano**	*Napoli*
♦ **Diego Scheggia**	*Napoli*
♦ **Anna Schettino**	*Napoli*
♦ **Klaus Schlueter**	*Monaco*
♦ **Annalisa Scopinaro**	*Roma*
♦ **Stefano Scotti**	*Milano*
♦ **Giovanna Scroccaro**	*Verona*
♦ **Sarah Adriana Scuderi**	*Messina*
♦ **Caterina Scuderi**	*Roma*
♦ **Damiana Scuteri**	*Catanzaro*
♦ **Christian Sepe**	*Roma*
♦ **Marta Serafini**	*Torino*
♦ **Melania Maria Serafini**	*Milano*
♦ **Valeria Serra**	*Cagliari*
♦ **Federica Servillo**	*Roma*
♦ **Carlotta Siddi**	*Cagliari*
♦ **Sandra Sigala**	*Brescia*
♦ **Denise Sighel**	*Trento*
♦ **Anna Signor**	*Padova*
♦ **Raffaele Simeoli**	*Roma*
♦ **Antonella Simone**	*Bologna*
♦ **Martina Simonelli**	*Napoli*
♦ **Giulia Sita**	*Bologna*
♦ **Martina Smimmo**	*Napoli*
♦ **Sara Soloperto**	*Torino*
♦ **Federica Sorà**	*Roma*
♦ **Raffaella Sorrentino**	*Napoli*
♦ **Rosalinda Sorrentino**	*Salerno*
♦ **Maria Angela Sortino**	*Catania*
♦ **Giovanni Sotgiu**	*Sassari*
♦ **Federico Spataro**	*Bari*
♦ **Giuseppe Spaziano**	*Napoli*
♦ **Antonio Speciale**	*Messina*
♦ **Edoardo Spina**	*Messina*
♦ **Laura Spinardi**	*Milano*

FACULTY

Andrea Spini	*Verona*
Liberata Sportiello	*Napoli*
Alessio Squassina	*Cagliari*
Marilisa Giustina Stano	*Verona*
Gabriele Stocco	*Trieste*
Ramona Stringhi	*Milano*
Chiara Sturaro	*Ferrara*
Jesse Swen	*Leiden*
Maurizio Taglialatela	*Napoli*
Mariangela Tamburello	*Brescia*
Andrea Tarozzi	*Bologna*
Anna Maria Tartaglione	*Roma*
Luisa Teixera Santos	*Lisbona*
Lara Testai	*Pisa*
Edoardo Tiziani	*Ferrara*
Giuseppe Toffoli	*Aviano*
Zaira Tomasoni	*Bologna*
Veronica Torre	*Genova*
Sebastiano Alfio Torrisi	*Catania*
Alessandra Toti	*Firenze*
Luigia Trabace	*Foggia*
Miriam Traficante	*Bologna*
Cristina Travelli	*Pavia*
Viviana Trezza	*Roma*
Gianluca Trifiro	*Verona*
Massimo Triggiani	*Salerno*
Samuele Trisolini	*Firenze*
Lisamaura Tulimiero	*Bari*
Vjola Tusha	*Perugia*
Michele Uda	*Roma*
Benedetta Vai	*Milano*
Giulia Valdiserra	*Pisa*
Adrian van den Hoven	*Bruxelles*
Valentina Vellecco	*Napoli*
Daniel Venturi	*Oxford*
Stefania Vetrano	*Milano*
Davor Virag	*Zagreb*
Roberta Vitale	*Salerno*
Annabella Vitalone	*Roma*
Umberto Vitolo	*Torino*
Giacomo Vitturi	*Verona*
Entela Xoxi	*Roma*
Erica Zamberletti	*Varese*
Serena Zamponi	*Roma*
Salvatore Zarrella	*Salerno*
Soami Filippo Zenoni	*Roma*
Francesca Zimetti	*Parma*
Andrea Zini	*Bologna*
Giulia Zudeh	*Trieste*